Biocept (BIOCQ) 10-Q 13 Aug 20 2020 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2020	Aug. 07, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Trading Symbol	BIOC
Entity Registrant Name	BIOCEPT INC
Entity Central Index Key	0001044378
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		133,934,314
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-36284
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	80-0943522
Entity Address, Address Line One	5810 Nancy Ridge Drive
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92121
City Area Code	858
Local Phone Number	320-8200
Title of 12(b) Security	Common Stock, par value $.0001 per share
Entity Shell Company	false
Entity Current Reporting Status	Yes
Security Exchange Name	NASDAQ

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Current assets:
Cash	$ 24,053,269	$ 9,301,406
Accounts receivable, net	3,179,217	3,527,078
Inventories, net	973,684	767,986
Prepaid expenses and other current assets	852,067	296,127
Total current assets	29,058,237	13,892,597
Fixed assets, net	1,336,726	1,504,330
Lease right-of-use assets - operating	587,839	729,330
Lease right-of-use assets - finance	2,035,610	1,606,387
Total assets	33,018,412	17,732,644
Current liabilities:
Accounts payable	1,933,025	2,011,827
Accrued liabilities	1,871,798	1,980,204
Current portion of lease liabilities - operating	603,999	842,452
Current portion of lease liabilities - finance	787,361	724,329
Supplier financings	435,376
Total current liabilities	5,631,559	5,558,812
Non-current portion of lease liabilities - finance	1,301,910	973,189
Total liabilities	6,933,469	6,532,001
Commitments and contingencies (see Note 10)
Shareholders’ equity:
Preferred stock, $0.0001 par value, 5,000,000 authorized; 2,133 shares issued and outstanding at December 31, 2019 and June 30, 2020.
Common stock, $0.0001 par value, 150,000,000 authorized; 54,738,485 issued and outstanding at December 31, 2019; 131,213,237 issued and outstanding at June 30, 2020.	13,121	5,474
Additional paid-in capital	286,622,426	256,912,358
Accumulated deficit	(260,550,604)	(245,717,189)
Total shareholders’ equity	26,084,943	11,200,643
Total liabilities and shareholders’ equity	$ 33,018,412	$ 17,732,644

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	2,133	2,133
Preferred stock, shares outstanding	2,133	2,133
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	131,213,237	54,738,485
Common stock, shares outstanding	131,213,237	54,738,485

Condensed Statements of Operati

Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Statement [Abstract]
Net revenues	$ 917,471	$ 1,191,323	$ 2,364,020	$ 2,215,562
Costs and expenses:
Cost of revenues	2,517,902	2,673,323	5,464,760	5,272,687
Research and development expenses	1,588,716	1,148,280	2,901,392	2,371,571
General and administrative expenses	1,911,239	1,676,310	3,815,672	3,358,147
Sales and marketing expenses	1,333,271	1,614,732	2,798,386	2,989,292
Total costs and expenses	7,351,128	7,112,645	14,980,210	13,991,697
Loss from operations	(6,433,657)	(5,921,322)	(12,616,190)	(11,776,135)
Other income/ (expense):
Interest expense	(55,646)	(63,574)	(112,342)	(125,548)
Warrant inducement expense		(1,831,116)	(2,102,109)	(1,831,116)
Total other income/ (expense):	(55,646)	(1,894,690)	(2,214,451)	(1,956,664)
Loss before income taxes	(6,489,303)	(7,816,012)	(14,830,641)	(13,732,799)
Net loss and comprehensive loss	(6,489,303)	(7,816,012)	(14,830,641)	(13,732,799)
Deemed dividend related to warrants down round provision			(2,774)	(99,743)
Net loss attributable to common shareholders	$ (6,489,303)	$ (7,816,012)	$ (14,833,415)	$ (13,832,542)
Weighted-average shares outstanding used in computing net loss per share attributable to common shareholders:
Basic	127,173,744	20,466,224	103,086,834	16,670,184
Diluted	127,173,744	20,466,224	103,086,834	16,670,184
Net loss per common share:
Basic	$ (0.05)	$ (0.38)	$ (0.14)	$ (0.83)
Diluted	$ (0.05)	$ (0.38)	$ (0.14)	$ (0.83)

Condensed Statements of Shareho

Condensed Statements of Shareholders' Equity - USD ($)	Total	January 2019 Financing Transaction [Member]	February 2019 Financing Transaction [Member]	January 2019 Financing Transaction Overallotment [Member]	March 2019 Financing Transaction [Member]	March 2, 2020 Financing Transaction [Member]	March 4, 2020 Financing Transaction [Member]	December 2019 Financing Transaction Overallotment [Member]	April 2020 Financing Transaction [Member]	Common Stock [Member]	Common Stock [Member]Cashless Warrants [Member]	Common Stock [Member]January 2019 Financing Transaction [Member]	Common Stock [Member]February 2019 Financing Transaction [Member]	Common Stock [Member]January 2019 Financing Transaction Overallotment [Member]	Common Stock [Member]March 2019 Financing Transaction [Member]	Common Stock [Member]March 2, 2020 Financing Transaction [Member]	Common Stock [Member]March 4, 2020 Financing Transaction [Member]	Common Stock [Member]December 2019 Financing Transaction Overallotment [Member]	Common Stock [Member]April 2020 Financing Transaction [Member]	SeriesA Convertible Preferred Stock [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member]Cashless Warrants [Member]	Additional Paid-in Capital [Member]January 2019 Financing Transaction [Member]	Additional Paid-in Capital [Member]February 2019 Financing Transaction [Member]	Additional Paid-in Capital [Member]January 2019 Financing Transaction Overallotment [Member]	Additional Paid-in Capital [Member]March 2019 Financing Transaction [Member]	Additional Paid-in Capital [Member]March 2, 2020 Financing Transaction [Member]	Additional Paid-in Capital [Member]March 4, 2020 Financing Transaction [Member]	Additional Paid-in Capital [Member]December 2019 Financing Transaction Overallotment [Member]	Additional Paid-in Capital [Member]April 2020 Financing Transaction [Member]	Accumulated Deficit [Member]
Beginning balance at Dec. 31, 2018	$ 3,042,519									$ 463											$ 223,499,634										$ (220,457,578)
Beginning balance, shares at Dec. 31, 2018										4,629,174										4,417
Stock-based compensation expense	102,459																				102,459
Shares issued upon exercise of common stock warrants	4,748									$ 1											4,747
Shares issued upon exercise of common stock warrants, shares										5,985
Deemed dividends related to warrants downround provision																					99,743										(99,743)
Shares and warrants issued, net of issuance costs		$ 2,032,311	$ 6,602,735	$ 592,306	$ 7,553,793							$ 99	$ 625	$ 54	$ 595								$ 2,032,212	$ 6,602,110	$ 592,252	$ 7,553,198
Shares and warrants issued, net of issuance costs, shares												990,000	6,250,000	538,867	5,950,000
Shares issued upon conversion of preferred stock										$ 50											(50)
Shares issued upon conversion of preferred stock, shares										503,438										(2,278)
Net loss	(5,916,787)																														(5,916,787)
Ending balance at Mar. 31, 2019	14,014,084									$ 1,887											240,486,305										(226,474,108)
Ending balance, shares at Mar. 31, 2019										18,867,464										2,139
Beginning balance at Dec. 31, 2018	3,042,519									$ 463											223,499,634										(220,457,578)
Beginning balance, shares at Dec. 31, 2018										4,629,174										4,417
Deemed dividends related to warrants downround provision	99,743
Net loss	(13,732,799)
Ending balance at Jun. 30, 2019	13,099,551									$ 2,302											247,387,369										(234,290,120)
Ending balance, shares at Jun. 30, 2019										23,018,235										2,133
Beginning balance at Dec. 31, 2018	3,042,519									$ 463											223,499,634										(220,457,578)
Beginning balance, shares at Dec. 31, 2018										4,629,174										4,417
Net loss	(25,100,000)
Ending balance at Dec. 31, 2019	11,200,643									$ 5,474											256,912,358										(245,717,189)
Ending balance, shares at Dec. 31, 2019										54,738,485										2,133
Beginning balance at Mar. 31, 2019	14,014,084									$ 1,887											240,486,305										(226,474,108)
Beginning balance, shares at Mar. 31, 2019										18,867,464										2,139
Stock-based compensation expense	224,641																				224,641
Shares issued upon exercise of common stock warrants	4,845,722									$ 415											4,845,307
Shares issued upon exercise of common stock warrants, shares										4,149,445
Shares issued upon conversion of preferred stock, shares										1,326										(6)
Warrant inducement expense	1,831,116																				1,831,116
Net loss	(7,816,012)																														(7,816,012)
Ending balance at Jun. 30, 2019	13,099,551									$ 2,302											247,387,369										(234,290,120)
Ending balance, shares at Jun. 30, 2019										23,018,235										2,133
Beginning balance at Dec. 31, 2019	11,200,643									$ 5,474											256,912,358										(245,717,189)
Beginning balance, shares at Dec. 31, 2019										54,738,485										2,133
Stock-based compensation expense	142,964																				142,964
Shares issued upon exercise of common stock warrants	2,306,708									$ 696	$ 608										2,306,012	$ (608)
Shares issued upon exercise of common stock warrants, shares										6,961,407	6,080,000
Deemed dividends related to warrants downround provision																					2,774										(2,774)
Shares and warrants issued, net of issuance costs						$ 8,565,500	$ 6,093,561	$ 659,958								$ 2,300	$ 1,600	$ 193									$ 8,563,200	$ 6,091,961	$ 659,765
Shares and warrants issued, net of issuance costs, shares																23,000,000	16,000,000	1,927,500
Warrant inducement expense	2,102,109																				2,102,109
Net loss	(8,341,338)																														(8,341,338)
Ending balance at Mar. 31, 2020	22,730,105									$ 10,871											276,780,535										(254,061,301)
Ending balance, shares at Mar. 31, 2020										108,707,392										2,133
Beginning balance at Dec. 31, 2019	11,200,643									$ 5,474											256,912,358										(245,717,189)
Beginning balance, shares at Dec. 31, 2019										54,738,485										2,133
Deemed dividends related to warrants downround provision	2,774
Net loss	(14,830,641)
Ending balance at Jun. 30, 2020	26,084,943									$ 13,121											286,622,426										(260,550,604)
Ending balance, shares at Jun. 30, 2020										131,213,237										2,133
Beginning balance at Mar. 31, 2020	22,730,105									$ 10,871											276,780,535										(254,061,301)
Beginning balance, shares at Mar. 31, 2020										108,707,392										2,133
Stock-based compensation expense	194,236																				194,236
Shares issued upon exercise of common stock warrants	72,608									$ 20											72,588
Shares issued upon exercise of common stock warrants, shares										205,845
Shares and warrants issued, net of issuance costs									$ 9,577,297										$ 2,230											$ 9,575,067
Shares and warrants issued, net of issuance costs, shares																			22,300,000
Net loss	(6,489,303)																														(6,489,303)
Ending balance at Jun. 30, 2020	$ 26,084,943									$ 13,121											$ 286,622,426										$ (260,550,604)
Ending balance, shares at Jun. 30, 2020										131,213,237										2,133

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash Flows from Operating Activities
Net loss	$ (14,830,641)	$ (13,732,799)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	477,396	450,984
Amortization of right-of-use assets	(96,962)	(75,613)
Inventory reserve	54,202	8,872
Stock-based compensation	337,200	327,100
Warrant inducement expense	2,102,109	1,831,116
Loss on disposal of fixed assets	459
Increase/(decrease) in cash resulting from changes in:
Accounts receivable, net	347,861	(634,630)
Inventory	(259,900)	(27,122)
Prepaid expenses and other current assets	11,232	233,153
Accounts payable	(4,916)	(71,720)
Accrued liabilities	(108,406)	(279,244)
Net cash used in operating activities	(11,970,366)	(11,969,903)
Cash Flows from Investing Activities:
Purchases of fixed assets	(35,457)	(86,476)
Net cash used in investing activities	(35,457)	(86,476)
Cash Flows from Financing Activities:
Net proceeds from issuance of common stock and warrants	24,236,358	16,779,772
Proceeds from exercise of common stock warrants	2,379,316	2,513,172
Proceeds from warrant exercise inducement, net		2,337,298
Proceeds from exercise of overallotment warrants	659,958
Payments on finance leases	(311,576)	(277,250)
Payments on supplier and other third-party financings	(206,370)	(129,389)
Net cash provided by financing activities	26,757,686	21,223,603
Net increase in Cash	14,751,863	9,167,224
Cash at Beginning of Period	9,301,406	3,423,373
Cash at End of Period	24,053,269	12,590,597
Cash paid during the period for:
Interest	$ 112,342	$ 125,548

Condensed Statements of Cash _2

Condensed Statements of Cash Flows (Unaudited) (Parenthetical) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Financed insurance premium through third party financing	$ 567,000	$ 393,000
Fixed assets purchased under finance lease obligations	703,000	149,000
Unpaid fixed assets	57,000	53,000	$ 32,000	$ 25,000
Operating lease, right-of-use asset	587,839		729,330
Operating lease liability	603,999
Lease right-of-use assets	2,035,610		$ 1,606,387
Deemed dividends related warrants down round provision	2,774	99,743
Proceeds from exercise of common stock warrants		2,337,298
Proceeds from exercise of common stock warrants	2,379,316	$ 2,513,172
February 2019 March 2019 Warrant Repricing and Exchange Transaction [Member]
Proceeds from exercise of common stock warrants	$ 2,300,000
Warrant [Member]
Stock price	$ 0.3495
ASC Topic 842 [Member]
Operating lease, right-of-use asset	$ 1,900,000
ASC Topic 842 [Member] | San Diego, California [Member]
Operating lease, right-of-use asset	482,000
Operating lease liability	482,000
Property, Plant and Equipment [Member] | ASC Topic 842 [Member]
Lease right-of-use assets	$ 1,400,000

The Company, Business Activitie

The Company, Business Activities and Basis of Presentation	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
The Company, Business Activities and Basis of Presentation	1. The Company, Business Activities and Basis of Presentation The Company and Business Activities The Company was founded in California in May 1997 and is an early stage molecular oncology diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, assays utilizing a standard blood sample, or liquid biopsy. The Company’s current and planned assays are intended to provide information to aid healthcare providers to identify specific oncogenic alterations that may qualify a subset of cancer patients for targeted therapy at diagnosis, progression or for monitoring in order to identify specific resistance mechanisms. Sometimes traditional procedures, such as surgical tissue biopsies, result in tumor tissue that is insufficient and/or unable to provide the molecular subtype information necessary for clinical decisions. The Company’s assays, performed on blood, have the potential to provide more contemporaneous information on the characteristics of a patient’s disease when compared with tissue biopsy and radiographic imaging. Additionally, commencing in October 2017, the Company’s pathology partnership program, branded as Empower TC TM , provides the unique ability for pathologists to participate in the interpretation of liquid biopsy results and is available to pathology practices and hospital systems throughout the United States. Further, sales to laboratory supply distributors of the Company’s proprietary blood collection tubes commenced in June 2018, which allow for the intact transport of liquid biopsy samples for research use only, or RUO, from regions around the world. The Company operates a clinical laboratory that is CLIA-certified (under the Clinical Laboratory Improvement Amendment of 1988) and CAP-accredited (by the College of American Pathologists), and manufactures cell enrichment and extraction microfluidic channels, related equipment and certain reagents to perform the Company’s diagnostic assays in a facility located in San Diego, California. CLIA certification and accreditation are required before any clinical laboratory may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, treatment of disease, or assessment of health. The assays the Company offers are classified as laboratory developed tests under the CLIA regulations. In July 2013, the Company effected a reincorporation to Delaware by merging itself with and into Biocept, Inc., a Delaware corporation, which had been formed to be and was a wholly-owned subsidiary of the Company since July 23, 2013. Basis of Presentation The accompanying unaudited condensed financial statements and notes are prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, and on the basis that the Company will continue as a going concern (see Note 2). The accompanying unaudited condensed financial statements and notes do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern. The unaudited condensed financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission, or SEC, instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed financial statements are unaudited and do not contain all the information required by GAAP to be included in a full set of financial statements. The balance sheet at December 31, 2019 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited financial statements for the year ended December 31, 2019, filed with the U.S. Securities and Exchange Commission, or SEC, with our Annual Report on Form 10-K on March 27, 2020 include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year. Significant Accounting Policies During the three and six months ended June 30, 2020, there were no changes to our significant accounting policies as described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, except as described in Recent Accounting Pronouncements below. Revenue Recognition and Accounts Receivable The Company's commercial revenues are generated from diagnostic services provided to patient’s physicians and billed to third-party insurance payers such as managed care organizations, Medicare and Medicaid and patients for any deductibles, coinsurance or copayments that may be due. Commencing on January 1, 2018, the Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers, or ASC 606, which requires that an entity recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. Contracts For its commercial revenues, while the Company markets directly to physicians, its customer is the patient. Patients do not enter into direct agreements with the Company, however, a patient’s insurance coverage requirements would dictate whether or not any portion of the cost of the tests would be patient responsibility. Accordingly, the Company establishes contracts with commercial insurers in accordance with customary business practices, as follows: • Approval of a contract is established via the order and accession, which are submitted by the patient’s physician. • The Company is obligated to perform its diagnostic services upon receipt of a sample from a physician, and the patient and/or applicable payer are obligated to reimburse the Company for services rendered based on the patient’s insurance benefits. • Payment terms are a function of a patient’s existing insurance benefits, including the impact of coverage decisions with CMS and applicable reimbursement contracts established between the Company and payers, unless the patient is a self-pay patient, whereby the Company bills the patient directly after the services are provided. • On ce the Company delivers a patient’s assay result to the ordering physician, the contract with a patient has commercial substance, as the Company is legally able to collect payment and bill an insurer and/or patient, regardless of payer contract status or patient insurance benefit status. • Consideration associated with commercial revenues is considered variable and constrained until fully adjudicated, with net revenues recorded to the extent that it is probable that a significant reversal will not occur. The Company’s development services revenues are supported by contractual agreements and generated from assay development services provided to entities, as well as certain other diagnostic services provided to physicians, and revenues are recognized upon delivery of the performance obligations in the contract. Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service, or a bundle of goods or services, to the customer. For its commercial and development services revenues, the Company’s contracts have a single performance obligation, which is satisfied upon rendering of services, which culminates in the delivery of a patient’s assay result(s) to the ordering physician or entity. The duration of time between accession receipt and delivery of a valid assay result to the ordering physician or entity is typically less than two weeks. Accordingly, the Company elected the practical expedient and therefore, does not disclose the value of unsatisfied performance obligations. Transaction Price The transaction price is the amount of consideration that the Company expects to collect in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties, such as sales taxes. The consideration expected from a contract with a customer may include fixed amounts, variable amounts, or both. The Company’s gross commercial revenues billed, and corresponding gross accounts receivable, are subject to estimated deductions for such allowances and reserves to arrive at reported net revenues, which relate to differences between amounts billed and corresponding amounts estimated to be subsequently collected, and is deemed to be variable although the variability is not explicitly stated in any contract. Rather, the implied variability is due to several factors, such as the payment history or lack thereof for third-party payers, reimbursement rate changes for contracted and non-contracted payers, any patient co-payments, deductibles or compliance incentives, the existence of secondary payers and claim denials. The Company estimates the The Company limits the amount of variable consideration included in the transaction price to the unconstrained portion of such consideration. Revenue is recognized up to the amount of variable consideration that is not subject to a significant reversal until additional information is obtained or the uncertainty associated with the additional payments or refunds is subsequently resolved. Differences between original estimates and subsequent revisions, including final settlements, represent changes in the estimate of variable consideration and are included in the period in which such revisions are made. The Company monitors its estimates of transaction price to depict conditions that exist at each reporting date. If the Company subsequently determines that it will collect more consideration than it originally estimated for a contract with a customer, it will account for the change as an increase in the estimate of the transaction price in the period identified as an increase to revenue. Similarly, if the Company subsequently determines that the amount it expects to collect from a customer is less than it originally estimated, it will generally account for the change as a decrease in the estimate of the transaction price as a decrease to revenue, provided that such downward adjustment does not result in a significant reversal of cumulative revenue recognized. Revenue recognized from changes in transaction prices was not significant during the three and six months ended June 30, 2019 and 2020. Allocate Transaction Price For the Company’s commercial revenues, the entire transaction price is allocated to the single performance obligation contained in a contract with a customer. For the Company’s development services revenues, the contracted transaction price is allocated to each single performance obligation contained in a contract with a customer as performed. Point-in-time Recognition The Company’s single performance obligation is satisfied at a point in time, and that point in time is defined as the date a patient’s successful assay result is delivered to the patient’s ordering physician or entity. The Company considers this date to be the time at which the patient obtains control of the promised diagnostic assay service. Contract Balances The timing of revenue recognition, billings and cash collections results in accounts receivable recorded in the Company’s condensed balance sheets. Generally, billing occurs subsequent to delivery of a patient’s test result to the ordering physician or entity, resulting in an account receivable. Practical Expedients The Company does not adjust the transaction price for the effects of a significant financing component, as at contract inception, the Company expects the collection cycle to be one year or less. The Company expenses sales commissions when incurred because the amortization period is one year or less, which are recorded within sales and marketing expenses. The Company incurs certain other costs that are incurred regardless of whether a contract is obtained. Such costs are primarily related to legal services and patient communications. These costs are expensed as incurred and recorded within general and administrative expenses. Disaggregation of Revenue and Concentration of Risk The composition of the Company’s net revenues recognized during the three and six months ended June 30, 2019 and 2020, disaggregated by source and nature, are as follows: For the three months ended June 30, For the six months ended June 30, 2019 2020 2019 2020 Net revenues from contracted payers* $ 489,901 $ 261,620 $ 971,320 $ 761,808 Net revenues from non-contracted payers 628,477 579,398 1,125,847 1,396,811 Development services revenues 45,081 38,453 87,579 98,782 Kits and Blood Collection Tubes (BCT) 27,864 38,000 30,816 106,619 Total net revenues $ 1,191,323 $ 917,471 $ 2,215,562 $ 2,364,020 *Includes Medicare and Medicare Advantage, as reimbursement amounts are fixed. For the three months ended June 30, For the six months ended June 30, 2019 2020 2019 2020 Net commercial revenues recognized upon delivery $ 1,118,378 $ 841,018 $ 2,009,364 $ 2,158,619 Development services revenues recognized upon delivery 45,081 38,453 87,579 98,782 Commercial revenues recognized upon cash collection — — 87,803 — Kits and Blood Collection Tubes (BCT) 27,864 38,000 30,816 106,619 Total net revenues $ 1,191,323 $ 917,471 $ 2,215,562 $ 2,364,020 Concentrations of credit risk with respect to revenues are primarily limited to geographies to which the Company provides a significant volume of its services, and to specific third-party payers of the Company’s services such as Medicare, insurance companies, and other third-party payers. The Company’s client base consists of many geographically dispersed clients diversified across various customer types. The Company's third-party payers that represent more than 10% of total net revenues in any period presented, as well as their related net revenue amount as a percentage of total net revenues, during the three and six months ended June 30, 2019 and 2020 were as follows: For the three months ended June 30, For the six months ended June 30, 2019 2020 2019 2020 Medicare and Medicare Advantage 43 % 30 % 45 % 34 % Blue Cross Blue Shield 20 % 29 % 17 % 29 % United Healthcare 8 % 8 % 10 % 6 % The Company's third-party payers that represent more than 10% of total net accounts receivable, and their related net accounts receivable balance as a percentage of total net accounts receivable, at December 31, 2019 and June 30, 2020 were as follows: December 31, 2019 June 30, 2020 Blue Cross Blue Shield 26 % 30 % Medicare and Medicare Advantage 17 % 13 % United Healthcare 12 % 11 % Aetna 7 % 11 % Recent Accounting Pronouncements In November 2018, the FASB issued authoritative guidance clarifying the interaction between Collaborative Arrangements (Topic 808) and Revenue from Contracts with Customers (Topic 606) to address diversity in practice related to how companies account for collaborative arrangements. For public companies, this guidance is effective for fiscal years beginning after December 15, 2019, including interim periods within that fiscal year. Early adoption is permitted, but no earlier than an entity’s adoption date of Revenue from Contracts with Customers (Topic 606). The Company adopted this guidance for the fiscal year beginning on January 1, 2020, and determined that the adoption of this guidance does not have a material impact on its financial statements or disclosures.

Liquidity and Going Concern Unc

Liquidity and Going Concern Uncertainty	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Liquidity and Going Concern Uncertainty	2. Liquidity and Going Concern Uncertainty As of June 30, 2020, the Company had $24.1 million of cash and an accumulated deficit of $260.6 million. For the year ended December 31, 2019 and the six months ended June 30, 2020, the Company incurred net losses of $25.1 million and $14.8 million, respectively. At June 30, 2020, the Company had aggregate net interest-bearing indebtedness of $2.1 million, of which $787,000 was due within one year, in addition to $2.4 million of other non-interest-bearing current liabilities. While Management believes that, absent the COVID-19 pandemic, based on historical and planned cash usage, the Company’s current cash would have supported its operations through most of 2021, due to the uncertainty introduced by the impact of COVID-19 on revenues and cash usage, there is uncertainty as to the period of time for which existing cash can support the Company’s ongoing operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern for the one-year period following the date that these financial statements were issued. The accompanying condensed financial statements and notes have been prepared assuming that the Company will continue as a going concern. The accompanying condensed financial statements and notes do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern. While the Company is currently in the commercialization stage of operations, the Company has not yet achieved profitability and anticipates that it will continue to incur net losses and negative cash flows from operations for the foreseeable future. Historically, the Company’s principal sources of cash have included proceeds from the issuance of common and preferred stock, proceeds from the exercise of warrants to purchase common stock, proceeds from the issuance of debt, and revenues from laboratory services. The Company’s principal uses of cash have included cash used in operations, payments relating to purchases of property and equipment and repayments of borrowings. The Company expects that the principal uses of cash in the future will be for continuing operations, hiring of sales and marketing personnel and increased sales and marketing activities, funding of research and development, capital expenditures, and general working capital requirements. The Company expects that, as revenues grow, sales and marketing and research and development expenses will continue to grow, albeit at a slower rate and, as a result, the Company will need to generate significant growth in net revenues to achieve and sustain income from operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern for the one-year period following the date that these financial statements were issued. The accompanying financial statements and notes have been prepared assuming that the Company will continue as a going concern. The accompanying financial statements and notes do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern. On March 11, 2020 the World Health Organization declared COVID-19 a global pandemic and recommended containment and mitigation measures worldwide. In addition, as we are located in California, we are currently under a shelter in place mandate and many of our clients worldwide are similarly impacted. As a healthcare provider, we are allowed to remain open in compliance with the shelter in place mandate and continue to provide critical information for patients diagnosed with cancer. However, the COVID-19 pandemic continues to evolve, and the extent to which COVID-19 may impact our business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. We estimate that the COVID-19 pandemic led to an approximate 15 to 25% decline in commercial volume from current customers, and also impacted opportunities for us to gain new customers with the closing of many physician offices and labs. We are continuing to vigilantly monitor the situation with our primary focus on the health and safety of our employees and clients. In January 2020, the Company issued an aggregate of 6,927,258 shares of its common stock pursuant to the exercise of certain warrants issued by the Company in February 2019 and March 2019, as part of a warrant repricing and exchange transaction. As part of the warrant repricing and exchange transaction, the Company issued an aggregate of 6,927,258 new warrants in exchange for the exercise of the February 2019 and March 2019 warrants and received net proceeds of approximately $2.3 million. As a result of the warrant repricing, the exercise price of warrants to purchase an aggregate of 896,578 shares of common stock issued by the Company in January 2018 was adjusted from $0.405 to $0.3495 per share. In January 2020, the Company issued 1,927,500 shares of common stock pursuant to the partial exercise of the underwriters’ overallotment option from the Company’s December 2019 public offering. The net proceeds to the Company from the overallotment closing, was approximately $700,000. On March 2, 2020, the Company received net cash proceeds of approximately $8.6 million from a registered direct offering to certain institutional investors of 23,000,000 shares of common stock at a negotiated purchase price of $0.40 per share. On March 4, 2020, the Company received net cash proceeds of approximately $6.1 million from a registered direct offering to certain institutional investors of 16,000,000 shares of common stock at a negotiated purchase price of $0.41 per share. On April 16, 2020, the Company received net cash proceeds of approximately $9.6 million from a registered direct offering to certain institutional investors of 22,300,000 shares of common stock at a negotiated purchase price of $0.46 per share. Management’s Plan to Continue as a Going Concern In order to continue as a going concern, the Company will need, among other things, additional capital resources. Until the Company can generate significant cash from operations, including assay revenues, management’s plans to obtain such resources for the Company include proceeds from offerings of the Company’s equity securities or debt, cash received from the exercise of outstanding common stock warrants, or transactions involving product development, technology licensing or collaboration. Management can provide no assurances that any sources of a sufficient amount of financing will be available to the Company on favorable terms, if at all. Based on the above, the Company’s management concluded that the going concern uncertainty has not been alleviated and as such, there is substantial doubt about the Company’s ability to continue as a going concern as of June 30, 2020.

Sales of Equity Securities

Sales of Equity Securities	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Sales of Equity Securities	3. Sales of Equity Securities On January 18, 2019, the Company completed an offering of 990,000 shares of its common stock. The shares were sold at a purchase price of $2.25 per share and the net proceeds to the Company from this offering were approximately $2.0 million, after deducting expenses related to the offering including dealer-manager fees and expenses. On February 12, 2019, the Company received net cash proceeds of approximately $6.6 million as a result of the closing of a follow-on public offering of 6,250,000 shares of its common stock and warrants to purchase up to an aggregate of 6,250,000 shares of its common stock at a combined offering price of $1.20 per unit. All warrants sold in this offering have an exercise price of $1.20 per share, are exercisable immediately and expire five years from the date of issuance. In addition, the Company sold warrants to purchase up to an aggregate of 937,500 shares of the Company’s common stock in connection with the partial exercise of the over-allotment option granted to the underwriters. Upon closing of the transaction, warrants to purchase 915,000 shares were issued pursuant to the placement agents’ partial exercise of their overallotment. Pursuant to the down round adjustment feature of the January 2018 warrants, the exercise price of these warrants was adjusted to the $1.20 price per share offering price in the February 2019 financing transaction. On March 19, 2019, the Company received net cash proceeds of approximately $7.5 million as a result of completing a registered direct offering of 5,950,000 shares at a negotiated purchase price of $1.37 per share. In addition, in a concurrent private placement, the Company issued to purchasers a warrant to purchase one share of the Company’s common stock for each share purchased for cash in the offering. All warrants issued in this offering have an exercise price of $1.25 per share, are exercisable immediately upon issuance and expire 5.5 years following the date of issuance. In May 2019, the Company received cash proceeds of approximately $2.5 million from the exercise of 2,086,479 February 2019 warrants at $1.20 per share. On May 28, 2019, the Company entered into Warrant Exercise Agreements, or the Exercise Agreements, with certain of the holders of its existing warrants, or the Exercising Holders. Pursuant to the Exercise Agreements, the Exercising Holders and the Company agreed that, subject to any applicable beneficial ownership limitations, the Exercising Holders would cash exercise up to 20% of their Existing Warrants, or the Investor Warrants, into shares of common stock underlying such Existing Warrants, or the Exercised Shares. In order to induce the Exercising Holders to cash exercise the Investor Warrants, the Exercise Agreements provided for the issuance of new warrants, or Inducement Warrants, with such Inducement Warrants to be issued in an amount equal to 75% of the number of Exercised Shares underlying any Investor Warrants that was cash exercised by July 15, 2019. The Inducement Warrants were exercisable upon issuance and terminate on the date that is five-years and six-months following the initial exercise date. The Inducement Warrants have an exercise price per share of $1.31. A total of 2,062,966 Investor Warrants were exercised contemporaneously with the execution of the Exercise Agreements resulting in total proceeds to the Company of $2.3 million, net of investment banking fees. The Inducement Warrants issued in connection with the Exercise Agreement were considered inducement warrants and are classified in equity. The fair value of the warrants issued was approximately $1.8 million (see valuation assumptions in Note 4). The fair value of the Inducement Warrants of $1.8 million was expensed as warrant inducement expense in the accompanying condensed statements of operations for the three and six months ended June 30, 2019. In January 2020, the Company issued an aggregate of 6,927,258 shares of its common stock pursuant to the exercise of certain warrants issued by the Company in February 2019 and March 2019, as part of a warrant repricing and exchange transaction. As part of the warrant repricing and exchange transaction, the Company issued an aggregate of 6,927,258 new warrants in exchange for the exercise of the February 2019 and March 2019 warrants and received net proceeds of approximately $2.3 million. As a result of the warrant repricing, the exercise price of warrants to purchase an aggregate of 896,578 shares of common stock issued by the Company in January 2018 was adjusted from $0.405 to $0.3495 per share. In January 2020, the Company issued 1,927,500 shares of common stock pursuant to the partial exercise of the underwriters’ overallotment option from the Company’s December 2019 public offering. The net proceeds to the Company from the overallotment closing, was approximately $700,000. The warrants issued in connection with the warrant repricing and exchange transaction were considered inducement warrants and are classified in equity. In addition, the modification expense associated with the change in fair value due to the repricing of February and March 2019 warrants is recorded as inducement expense, which was approximately $191,000. The fair value of the warrants issued was approximately $1.9 million. The fair value of the inducement warrants and warrant modification of $2.1 million was expensed as warrant inducement expense in the accompanying condensed statements of operations for the six months ended June 30, 2020. On March 2, 2020, the Company sold and issued 23,000,000 shares of its common stock at a negotiated purchase price of $0.40 per share in a registered direct offering and received net cash proceeds of approximately $8.6 million after deducting placement agent fees and other expenses. On March 4, 2020, the Company sold and issued 16,000,000 shares of its common stock at a negotiated purchase price of $0.41 per share in a registered direct offering and received net cash proceeds of approximately $6.1 million after deducting placement agent fees and other expenses. On April 16, 2020, the Company sold and issued 22,300,000 shares of its common stock at a negotiated purchase price of $0.46 per share in a registered direct offering and received net cash proceeds of approximately $9.6 million after deducting placement agent fees and other expenses.

Fair Value Measurement

Fair Value Measurement	6 Months Ended
	Jun. 30, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurement	4. Fair Value Measurement The estimated nonrecurring fair value measurements associated with fixed asset purchases recorded as right-of-use asset finance lease obligations totaling approximately $703,000 during the six months ended June 30, 2020 were calculated as the present value of the lease payments based on contractual payment amounts and estimated market rates. Upon adoption of guidance in ASC Topic 842 Leases, the estimated fair value of the right-of-use operating lease asset was recorded based on present value of future lease payments based contractual payment amounts and estimated market rates in effect. Other Fair Value Measurements As of the closing of the Company’s February 12, 2019 offering, the estimated grant date fair value of approximately $0.95 per share associated with the warrants to purchase up to 7,165,000 shares of common stock issued in this offering, or a total of approximately $6.8 million, was recorded as an offset to additional paid-in capital on a relative fair value basis. All warrants sold in this offering have an exercise price of $1.20 per share, are exercisable immediately and expire five years from the date of issuance. The fair value of the warrants was estimated using a Black-Scholes model with the following assumptions: Beginning stock price $ 1.05 Exercise price $ 1.20 Expected dividend yield 0.00 % Discount rate-bond equivalent yield 2.49 % Expected life (in years) 5.00 Expected volatility 147.7 % As of the closing of the Company’s March 19, 2019 offering, the estimated grant date fair value of approximately $1.01 per share associated with the warrants to purchase up to 5,950,000 shares of common stock issued in this offering, or a total of approximately $6.0 million, was recorded as an offset to additional paid-in capital on a relative fair value basis. All warrants sold in this offering have an exercise price of $1.25 per share, are exercisable immediately and expire 5.5 years from the date of issuance. The fair value of the warrants was estimated using a Black-Scholes model with the following assumptions: Beginning stock price $ 1.12 Exercise price $ 1.25 Expected dividend yield 0.00 % Discount rate-bond equivalent yield 2.44 % Expected life (in years) 5.50 Expected volatility 140.0 % As of the closing of the Company’s May 2019 warrant inducement transaction, the estimated grant date fair value of approximately $1.18 per share associated with the Inducement Warrants to purchase up to 1,547,226 shares of common stock issued in the transaction, or a total of approximately $1.8 million, was recorded as a warrant inducement expense with an offset to additional paid-in capital. The Inducement Warrants have an exercise price of $1.31 per share, are exercisable immediately and expire 5.5 years from the date of issuance. The fair value of the Inducement Warrants was estimated using a Black-Scholes model with the following assumptions: Beginning stock price $ 1.29 Exercise price $ 1.31 Expected dividend yield 0.00 % Discount rate-bond equivalent yield 2.05 % Expected life (in years) 5.50 Expected volatility 145.9 % As of the closing of the Company’s January 2020 warrant repricing and exchange transaction, the estimated grant date fair value of approximately $0.28 per share associated with the warrants to purchase up to 6,927,258 shares of common stock issued in the transaction, or a total of approximately $1.9 million, was recorded as a warrant inducement expense with an offset to additional paid-in capital. All warrants issued in this warrant inducement transaction have an exercise price of $0.3495 per share, became exercisable beginning 6 months from issuance and expire 5.5 years from the date of issuance. The fair value of the warrants was estimated using a Black-Scholes model with the following assumptions: Beginning stock price $ 0.30 Exercise price $ 0.3495 Expected dividend yield 0.00 % Discount rate-bond equivalent yield 1.66 % Expected life (in years) 5.50 Expected volatility 150.33 % In addition to the inducement warrants issued in the Company’s January 2020 warrant repricing and exchange transaction, the Company adjusted the exercise prices of the February 2019 and March 2019 warrants from $1.20 and $1.25, respectively, to $0.3495 to induce exercise of these warrants. This price modification triggered the requirement for modification accounting of these warrants. Based on the applicable guidance, the modification required the Company to value the modified February 2019 and March 2019 warrants immediately prior to the modification of the exercise price and immediately following the modification and record the difference between the resulting two values as warrant inducement expense. The estimated fair value prior to modification of the February 2019 and March 2019 warrants was approximately $0.27 per share, whereas the estimated fair value of the February 2019 warrants increased to $0.29 due to the adjustment of the exercise price, and the estimated fair value of the March 2019 warrants increased to $0.30 per share. There were 2,167,258 February 2019 warrants and 4,760,000 March 2019 warrants eligible for this price modification and the resulting modification expense recorded as warrant inducement expenses were $60,000 and $130,000, respectively.

Balance Sheet Details

Balance Sheet Details	6 Months Ended
	Jun. 30, 2020
Balance Sheet Components [Abstract]
Balance Sheet Details	5. Balance Sheet Details The following provides certain balance sheet details: December 31, June 30, 2019 2020 Fixed Assets Machinery and equipment $ 2,857,538 $ 2,925,530 Furniture and office equipment 156,987 156,987 Computer equipment and software 1,552,891 1,552,891 Leasehold improvements 570,173 570,173 Construction in process 625,038 570,208 Total fixed assets, gross 5,762,627 5,775,789 Less accumulated depreciation and amortization (4,258,297 ) (4,439,063 ) Total fixed assets, net $ 1,504,330 $ 1,336,726 Accrued Liabilities Accrued payroll $ 298,855 $ 312,306 Accrued vacation 622,792 799,203 Accrued bonuses 748,742 525,034 Accrued sales commissions 89,562 88,546 Accrued other 220,253 146,709 Total accrued liabilities $ 1,980,204 $ 1,871,798

Leases

Leases	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Leases	6. Leases Effective January 1, 2019, the Company adopted US GAAP accounting rules in ASC Topic 842, Leases (ASC 842), using the modified retrospective method. The Company elected to follow the package of practical expedients provided under the transition guidance within ASC 842, and accordingly, did not reassess whether any expired or existing contracts are or contain leases, did not reassess expired or existing leases, and did not reassess initial direct costs for any existing leases. Upon adoption, the Company recorded an operating lease right-of-use asset and an operating lease liability on the balance sheet. In addition, assets under equipment leases previously classified as capital leases within Property, Plant and Equipment on the Company’s balance sheet were reclassified to finance lease right-of-use assets upon adoption of the guidance. Right-of-use assets and obligations were recognized based on the present value of remaining lease payments over the lease term. As the Company’s operating lease does not provide an implicit rate, an estimated incremental borrowing rate was used based on the information available at the adoption date in determining the present value of lease payments. Operating lease expense is recognized on a straight-line basis over the lease term. Variable lease costs such as common area costs and other operating costs are expensed as incurred. Leases with an initial term of 12 months or less are not recorded on the balance sheet. Finance Leases The Company leases certain laboratory equipment under arrangements previously accounted for as capital leases, classified on the Company’s balance sheet as fixed assets and related lease liabilities and depreciated on a straight-line basis over the lease term. Upon adoption of ASC 842, leased equipment previously classified as fixed assets totaling $1.4 million in net book value were reclassified to lease right-of-use assets in accordance with the guidance. The equipment under finance leases is depreciated on a straight-line basis over periods ranging from approximately 3 to 7 years. The total gross value of equipment capitalized under such lease arrangements was approximately $3,125,000 and $3,917,000 at December 31, 2019 and June 30, 2020, respectively. Total accumulated depreciation related to equipment under finance leases was approximately $1,606,000 and $1,885,000 at December 31, 2019 and June 30, 2020, respectively. Total depreciation expense related to equipment under finance leases during the three months ended June 30, 2019 and 2020 was approximately $89,000 and $130,000, and was approximately $231,000 and $274,000 during the six months ended June 30, 2019 and 2020, respectively. On January 31, 2019, the Company executed an equipment financing commitment with a third-party lender for total proceeds of approximately $149,000, which was funded by the lender on February 1, 2019. Under the terms of the equipment financing agreement, which was accounted for as a finance lease transaction, the principal balance plus interest for the equipment are to be repaid in full after 36 monthly installments of $5,013 totaling approximately $180,000 through February 2022. In February 2020, the Company entered into finance leases for a total capitalized amount of $197,000 for three pieces of equipment . Under the terms of the equipment financing agreement, which was accounted for as a finance lease transaction, the principal balance plus interest for the equipment are to be repaid in full in installments ranging from 48 to 60 monthly installments of $4,532 totaling approximately $265,000 through January 2025. In addition, in March 2020, the Company entered into a finance lease for a capitalized amount of $11,000 for an additional piece of equipment. Under the term of the equipment financing agreement, the principal amount plus interest are to be repaid in 48 monthly installments of $288 totaling approximately $14,000 through February 2024. In April 2020, the Company entered into finance leases for a capitalized amount of $161,000 for laboratory testing equipment and manufacturing tooling. Under the terms of the equipment financing agreement, which was accounted for as a finance lease transaction, the principal balance plus interest for the equipment are to be repaid in full in 60 monthly installments of $3,337 totaling approximately $185,000 through March 2025. In June 2020 the Company entered into finance leases for a capitalized amount of $334,000 for equipment and laboratory management software. Operating Lease The Company leases its primary laboratory and office facilities in San Diego, California. This lease is classified as an operating lease in accordance with the ASC 842 guidance. The average monthly cash payment for the operating lease is approximately $120,000 per month, with the original lease term initially scheduled to end on July 31, 2020. The Company recorded a lease right-of-use asset and lease liability of $1,930,000 and $2,201,000, respectively, as of January 1, 2019, based on present value of payments and an incremental borrowing rate of 4.5%. On June 5, 2020, the Company entered into a fifth amendment (the “Amendment”) to its lease agreement with ARE-SC Region No. 18, LLC, dated March 31, 2004, relating to its current facility in San Diego, California. Pursuant to the Amendment, the expiration date of the Lease was extended from July 31, 2020 to November 30, 2020. The monthly base rent during the extended term will be the current monthly rate paid by the Company. The Company will also pay additional rent and all other charges as set forth in the Lease through the expiration date. During the six months ended June 30, 2020, pursuant to the extension of the expiration date of the lease, the Company recorded an additional lease right-of-use asset and lease liability of $482,000. On June 1, 2020, the Company entered into a lease for a 39,000 square foot headquarters, manufacturing and laboratory facility in San Diego, California. The lease is anticipated to commence on December 1, 2020 and is for a term of 127 months from the commencement date. The average monthly cash payment for the lease is approximately $128,000 per month with initial monthly lease payments at $111,000 per month. In addition, the Company reviews agreements at inception to determine if they include a lease, and when they do, uses its incremental borrowing rate or implicit interest rate to determine the present value of the future lease payments. The following schedule sets forth the components of right-of-use lease assets as of December 31, 2019 and June 30, 2020 as follows: December 31, June 30, 2019 2020 Lease right-of-use assets: Operating 729,330 $ 587,839 Finance 1,606,387 2,035,610 Total $ 2,335,717 $ 2,623,449 The following schedule sets forth the current portion of operating and finance lease liabilities as of December 31, 2019 and June 30, 2020: December 31, June 30, 2019 2020 Current portion of lease liability: Operating 842,452 $ 603,999 Finance 724,329 787,361 Total $ 1,566,781 $ 1,391,360 The following schedule sets forth the long-term portion of operating and finance lease liabilities as of December 31, 2019 and June 30, 2020: December 31, June 30, 2019 2020 Long-term portion of lease liability: Operating $ — $ — Finance 973,189 1,301,910 Total $ 973,189 $ 1,301,910 The following schedule represents the components of lease expense for the three and six months ended June 30, 2019 and 2020: For the three months ended June 30, For the six months ended June 30, 2019 2020 2019 2020 Lease cost Finance lease cost Amortization of right-of-use assets $ 119,599 $ 129,576 $ 229,929 $ 274,106 Interest on lease liabilities 63,574 50,975 125,548 107,672 Operating lease cost 318,005 318,005 636,010 636,010 Total $ 501,178 $ 498,556 $ 991,487 $ 1,017,788 The following schedule sets forth the remaining future minimum lease payments outstanding under finance and operating leases, as well as corresponding remaining sales tax and maintenance obligation payments that are expensed as incurred and due within each respective year ending December 31, as well as the present value of the total amount of the remaining minimum lease payments as of June 30, 2020: Finance Operating Minimum Maintenance and Minimum Lease Sales Tax Obligation Lease Payments Payments Payments 2020 $ 471,266 $ 49,161 $ 610,810 2021 730,247 81,035 — 2022 606,797 69,481 — 2023 466,170 70,231 — Thereafter 255,733 23,163 — Total payments 2,530,213 293,071 610,810 Less amount representing interest (440,942 ) — (6,811 ) Present value of payments $ 2,089,271 $ 293,071 $ 603,999 The following schedule sets forth supplemental cash flow information related to operating and finance leases as of June 30, 2020: For the six months ended June 30, 2019 2020 Other information Operating cash flows from finance leases $ 125,548 $ 107,672 Operating cash flows from operating leases $ 711,624 $ 732,973 Financing cash flows from finance leases $ 277,250 $ 311,576 The aggregate weighted average remaining lease term was 3.41 years on finance leases and 0.09 years on operating leases as of June 30, 2020. The aggregate weighted average discount rate was 19.69% on finance leases and 4.5% on operating leases as of June 30, 2020. During the six months ended June 30, 2020, the Company added $703,000 of right of use assets in exchange for finance lease liabilities. In addition, upon adoption of the accounting guidance in ASC 842, $1.4 million of net machinery and equipment was reclassified to lease right-of-use assets related to assets under finance leases and $1.9 million of right-of-use facility lease was recorded under operating lease.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	7. Stock-Based Compensation Equity Incentive Plans The Company maintains two equity incentive plans: The Amended and Restated 2013 Equity Incentive Plan, or the 2013 Plan, and the 2007 Equity Incentive Plan, or the 2007 Plan. The 2013 Plan includes a provision that shares available for grant under the Company’s 2007 Plan become available for issuance under the 2013 Plan and are no longer available for issuance under the 2007 Plan. At the Company’s annual meeting of stockholders held on June 5, 2020, the Company’s stockholders approved amendments to the 2013 Plan, which included an increase in the number of non-inducement shares of common stock authorized for issuance under the 2013 Plan by 7,300,000 shares. As of June 30, 2020, under all plans, a total of 10,364,098 non-inducement shares were authorized for issuance, 2,571,712 shares had been issued with 2,453,885 non-inducement stock options and restricted stock units, or RSUs, underlying outstanding awards, and 7,919,339 non-inducement shares were available for grant. As of June 30, 2020, 118,368 inducement shares were authorized for issuance, 118,368 inducement shares had been issued under the 2013 Plan, with 117,534 inducement stock options and RSUs underlying outstanding awards and no inducement shares available for grant. Stock Options A summary of stock option activity for the six months ended June 30, 2020 is as follows: Weighted Average Weighted Remaining Number of Average Exercise Contractual Shares Price Per Share Term in Years Outstanding at December 31, 2019 2,732,023 $ 3.66 9.25 Granted 86,739 $ 0.43 Exercised — — Cancelled/forfeited/expired (247,050 ) $ 1.78 Outstanding at June 30, 2020 2,571,712 $ 3.73 8.80 Vested and unvested expected to vest at June 30, 2020 2,514,856 $ 3.80 8.62 The intrinsic values of options outstanding, options exercisable, and options vested and unvested expected to vest at December 31, 2019 and June 30, 2020 were each approximately zero. The assumptions used in the Black-Scholes pricing model for stock options granted during the six months ended June 30, 2020 were as follows: Stock and exercise prices $0.27 - $0.71 Expected dividend yield 0.00% Discount rate-bond equivalent yield 0.38% – 1.37% Expected life (in years) 5.0 – 5.96 Expected volatility 146.1% - 171.1% Restricted Stock A summary of RSU activity for the six months ended June 30, 2020 is as follows: Weighted Number of Average Grant Shares Date Fair Value Outstanding at December 31, 2019 360 $ 415.80 Granted — — Vested and issued — — Forfeited — — Outstanding at June 30, 2020 360 $ 415.80 Vested and unvested expected to vest at June 30, 2020 360 $ 415.80 At June 30, 2020, the intrinsic values of RSUs outstanding and RSUs unvested and expected to vest were each approximately $100. Of the 360 RSUs outstanding at June 30, 2020, all were fully vested. Stock-based Compensation Expense The following table presents the effects of stock-based compensation related to equity awards to employees and nonemployees on the unaudited condensed statements of operations and comprehensive loss during the periods presented: For the three months ended For the six months ended June 30, June 30, 2019 2020 2019 2020 Stock Options Cost of revenues $ 17,073 $ 30,752 $ 25,220 $ 53,565 Research and development expenses 36,922 29,082 65,116 53,517 General and administrative expenses 145,037 103,345 192,618 197,759 Sales and marketing expenses 25,609 31,057 44,146 32,359 Total expenses related to stock options $ 224,641 $ 194,236 $ 327,100 $ 337,200 Stock-based compensation expense was recorded net of estimated forfeitures of 0% - 8% per annum during each of the three and six months ended June 30, 2019 and 2020. As of June 30, 2020, total unrecognized share-based compensation expense related to unvested stock options and RSUs, adjusted for estimated forfeitures, was $1,547,918 and is expected to be recognized over a weighted-average period of approximately 2.8 years.

Common Stock Warrants Outstandi

Common Stock Warrants Outstanding	6 Months Ended
	Jun. 30, 2020
Other Liabilities Disclosure [Abstract]
Common Stock Warrants Outstanding	8. Common Stock Warrants Outstanding A summary of equity-classified common stock warrant activity for the six months ended June 30, 2020 is as follows: Average Weighted Remaining Number of Average Exercise Contractual Shares Price Per Share Term in Years Outstanding at December 31, 2019 27,484,249 $ 1.86 4.6 Issued 8,854,758 0.36 Exercised (21,254,752 ) 0.67 Expired (19,339 ) 140.40 Outstanding at June 30, 2020 15,064,916 $ 2.47 4.2 All warrants outstanding at June 30, 2020 are exercisable, except for the warrants issued in January 2020 pursuant to the repricing and exchange transaction, which have a term of 5.5 years and became exercisable on the six-month anniversary of issuance, July 10, 2020.

Net Loss per Common Share

Net Loss per Common Share	6 Months Ended
	Jun. 30, 2020
Earnings Per Share [Abstract]
Net Loss per Common Share	9. Net Loss per Common Share Basic and diluted net loss per common share is determined by dividing net loss applicable to common shareholders by the weighted-average common shares outstanding during the period. Because there is a net loss attributable to common shareholders for the three and six months ended June 30, 2019 and 2020, the outstanding RSUs, warrants, and common stock options have been excluded from the calculation of diluted loss per common share because their effect would be anti-dilutive. Therefore, the weighted-average shares used to calculate both basic and diluted loss per share are the same. The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding for the periods presented, as they would be anti-dilutive: For the six months ended June 30, 2019 2020 Preferred warrants outstanding (number of common stock equivalents) 17 — Common warrants outstanding 15,197,249 15,064,916 RSUs outstanding 360 360 Convertible preferred stock outstanding (number of common stock equivalents) 471,393 471,393 Common options outstanding 2,768,443 2,571,712 Total anti-dilutive common share equivalents 18,437,462 18,108,381

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2020
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	10. Commitments and Contingencies In the normal course of business, the Company may be involved in legal proceedings or threatened legal proceedings. The Company is not party to any legal proceedings or aware of any threatened legal proceedings that are expected to have a material adverse effect on its financial condition, results of operations or liquidity. During the three months ended June 30, 2019 and 2020, total expense recorded in the Company’s unaudited condensed statements of operations and comprehensive loss for sales tax and maintenance obligations associated with equipment financing arrangements was approximately $23,000 and $30,000, respectively, with approximately $47,000 and $62,000 recorded during the six months ended June 30, 2019 and 2020, respectively. At December 31, 2019 and June 30, 2020, approximately $78,000 and $75,000, respectively, of such sales tax and maintenance obligations incurred but not paid were recorded in accrued other liabilities in the Company’s balance sheet (see Note 5). Future amounts totaling approximately $293,000 for sales tax and maintenance obligations associated with financed equipment were due under equipment financing arrangements at June 30, 2020, which will be expensed as incurred (see Note 6).

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2020
Related Party Transactions [Abstract]
Related Party Transactions	11. Related Party Transactions A member of the Company’s management is the controlling person of Aegea Biotechnologies, Inc., or Aegea. On September 2, 2012, the Company entered into an Assignment and Exclusive Cross-License Agreement, or the Cross-License Agreement, with Aegea. The Company received payments totaling approximately $19,000 and $26,000 during the years ended December 31, 2018 and 2019, respectively, from Aegea as reimbursements for shared patent costs under the Cross-License Agreement. On December 11, 2019, the Company entered into a First Amendment to Assignment and Exclusive Cross-License Agreement with Aegea pursuant to which the Company obtained a royalty bearing license for a certain patent. The Company agreed to pay Aegea, effective January 1, 2019, a royalty of 10% on the Company’s sale of research use only, or RUO, and import research use only reagents and kits in the field of oncology, where the sample types are tissue, whole blood, bone marrow, cerebrospinal fluid or derivatives of any of the foregoing. As of December 31, 2019 and June 30, 2020, the Company has accrued approximately $7,500 and $3,000 for royalty expenses, respectively, related to this arrangement. On June 3, 2020, the Company announced entering into a development agreement with Aegea focused on the co-development by Biocept and Aegea of a highly sensitive PCR-based assay designed by Aegea for detecting the COVID-19 virus. Pursuant to the agreement, the Company will receive compensation for development services performed based on time and materials expended. During the three months ended June 30, 2020, the Company recorded development service revenues of approximately $2,100 and had approximately $2,100 accounts receivable due from Aegea as of June 30, 2020, related to this agreement.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	12. Subsequent Events In July 2020, the warrants issued in the January 2020 Warrant Exercise Inducement offering became exercisable. During the period between July 10, 2020 and August 7, 2020, holders exercised 5,027,667 warrants in cashless exercise transactions for 2,687,744 shares of the Company’s common stock. In addition, on August 7, 2020, holders of the Company’s January 2018 warrant exercised 33,333 warrants for $0.3495 per share.

The Company, Business Activit_2

The Company, Business Activities and Basis of Presentation (Policies)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
The Company and Business Activities	The Company and Business Activities The Company was founded in California in May 1997 and is an early stage molecular oncology diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, assays utilizing a standard blood sample, or liquid biopsy. The Company’s current and planned assays are intended to provide information to aid healthcare providers to identify specific oncogenic alterations that may qualify a subset of cancer patients for targeted therapy at diagnosis, progression or for monitoring in order to identify specific resistance mechanisms. Sometimes traditional procedures, such as surgical tissue biopsies, result in tumor tissue that is insufficient and/or unable to provide the molecular subtype information necessary for clinical decisions. The Company’s assays, performed on blood, have the potential to provide more contemporaneous information on the characteristics of a patient’s disease when compared with tissue biopsy and radiographic imaging. Additionally, commencing in October 2017, the Company’s pathology partnership program, branded as Empower TC TM , provides the unique ability for pathologists to participate in the interpretation of liquid biopsy results and is available to pathology practices and hospital systems throughout the United States. Further, sales to laboratory supply distributors of the Company’s proprietary blood collection tubes commenced in June 2018, which allow for the intact transport of liquid biopsy samples for research use only, or RUO, from regions around the world. The Company operates a clinical laboratory that is CLIA-certified (under the Clinical Laboratory Improvement Amendment of 1988) and CAP-accredited (by the College of American Pathologists), and manufactures cell enrichment and extraction microfluidic channels, related equipment and certain reagents to perform the Company’s diagnostic assays in a facility located in San Diego, California. CLIA certification and accreditation are required before any clinical laboratory may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, treatment of disease, or assessment of health. The assays the Company offers are classified as laboratory developed tests under the CLIA regulations. In July 2013, the Company effected a reincorporation to Delaware by merging itself with and into Biocept, Inc., a Delaware corporation, which had been formed to be and was a wholly-owned subsidiary of the Company since July 23, 2013.
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed financial statements and notes are prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, and on the basis that the Company will continue as a going concern (see Note 2). The accompanying unaudited condensed financial statements and notes do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern. The unaudited condensed financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission, or SEC, instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed financial statements are unaudited and do not contain all the information required by GAAP to be included in a full set of financial statements. The balance sheet at December 31, 2019 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited financial statements for the year ended December 31, 2019, filed with the U.S. Securities and Exchange Commission, or SEC, with our Annual Report on Form 10-K on March 27, 2020 include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year.
Significant Accounting Policies	Significant Accounting Policies During the three and six months ended June 30, 2020, there were no changes to our significant accounting policies as described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, except as described in Recent Accounting Pronouncements below.
Revenue Recognition and Accounts Receivable	Revenue Recognition and Accounts Receivable The Company's commercial revenues are generated from diagnostic services provided to patient’s physicians and billed to third-party insurance payers such as managed care organizations, Medicare and Medicaid and patients for any deductibles, coinsurance or copayments that may be due. Commencing on January 1, 2018, the Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers, or ASC 606, which requires that an entity recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. Contracts For its commercial revenues, while the Company markets directly to physicians, its customer is the patient. Patients do not enter into direct agreements with the Company, however, a patient’s insurance coverage requirements would dictate whether or not any portion of the cost of the tests would be patient responsibility. Accordingly, the Company establishes contracts with commercial insurers in accordance with customary business practices, as follows: • Approval of a contract is established via the order and accession, which are submitted by the patient’s physician. • The Company is obligated to perform its diagnostic services upon receipt of a sample from a physician, and the patient and/or applicable payer are obligated to reimburse the Company for services rendered based on the patient’s insurance benefits. • Payment terms are a function of a patient’s existing insurance benefits, including the impact of coverage decisions with CMS and applicable reimbursement contracts established between the Company and payers, unless the patient is a self-pay patient, whereby the Company bills the patient directly after the services are provided. • On ce the Company delivers a patient’s assay result to the ordering physician, the contract with a patient has commercial substance, as the Company is legally able to collect payment and bill an insurer and/or patient, regardless of payer contract status or patient insurance benefit status. • Consideration associated with commercial revenues is considered variable and constrained until fully adjudicated, with net revenues recorded to the extent that it is probable that a significant reversal will not occur. The Company’s development services revenues are supported by contractual agreements and generated from assay development services provided to entities, as well as certain other diagnostic services provided to physicians, and revenues are recognized upon delivery of the performance obligations in the contract. Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service, or a bundle of goods or services, to the customer. For its commercial and development services revenues, the Company’s contracts have a single performance obligation, which is satisfied upon rendering of services, which culminates in the delivery of a patient’s assay result(s) to the ordering physician or entity. The duration of time between accession receipt and delivery of a valid assay result to the ordering physician or entity is typically less than two weeks. Accordingly, the Company elected the practical expedient and therefore, does not disclose the value of unsatisfied performance obligations. Transaction Price The transaction price is the amount of consideration that the Company expects to collect in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties, such as sales taxes. The consideration expected from a contract with a customer may include fixed amounts, variable amounts, or both. The Company’s gross commercial revenues billed, and corresponding gross accounts receivable, are subject to estimated deductions for such allowances and reserves to arrive at reported net revenues, which relate to differences between amounts billed and corresponding amounts estimated to be subsequently collected, and is deemed to be variable although the variability is not explicitly stated in any contract. Rather, the implied variability is due to several factors, such as the payment history or lack thereof for third-party payers, reimbursement rate changes for contracted and non-contracted payers, any patient co-payments, deductibles or compliance incentives, the existence of secondary payers and claim denials. The Company estimates the The Company limits the amount of variable consideration included in the transaction price to the unconstrained portion of such consideration. Revenue is recognized up to the amount of variable consideration that is not subject to a significant reversal until additional information is obtained or the uncertainty associated with the additional payments or refunds is subsequently resolved. Differences between original estimates and subsequent revisions, including final settlements, represent changes in the estimate of variable consideration and are included in the period in which such revisions are made. The Company monitors its estimates of transaction price to depict conditions that exist at each reporting date. If the Company subsequently determines that it will collect more consideration than it originally estimated for a contract with a customer, it will account for the change as an increase in the estimate of the transaction price in the period identified as an increase to revenue. Similarly, if the Company subsequently determines that the amount it expects to collect from a customer is less than it originally estimated, it will generally account for the change as a decrease in the estimate of the transaction price as a decrease to revenue, provided that such downward adjustment does not result in a significant reversal of cumulative revenue recognized. Revenue recognized from changes in transaction prices was not significant during the three and six months ended June 30, 2019 and 2020. Allocate Transaction Price For the Company’s commercial revenues, the entire transaction price is allocated to the single performance obligation contained in a contract with a customer. For the Company’s development services revenues, the contracted transaction price is allocated to each single performance obligation contained in a contract with a customer as performed. Point-in-time Recognition The Company’s single performance obligation is satisfied at a point in time, and that point in time is defined as the date a patient’s successful assay result is delivered to the patient’s ordering physician or entity. The Company considers this date to be the time at which the patient obtains control of the promised diagnostic assay service. Contract Balances The timing of revenue recognition, billings and cash collections results in accounts receivable recorded in the Company’s condensed balance sheets. Generally, billing occurs subsequent to delivery of a patient’s test result to the ordering physician or entity, resulting in an account receivable. Practical Expedients The Company does not adjust the transaction price for the effects of a significant financing component, as at contract inception, the Company expects the collection cycle to be one year or less. The Company expenses sales commissions when incurred because the amortization period is one year or less, which are recorded within sales and marketing expenses. The Company incurs certain other costs that are incurred regardless of whether a contract is obtained. Such costs are primarily related to legal services and patient communications. These costs are expensed as incurred and recorded within general and administrative expenses. Disaggregation of Revenue and Concentration of Risk The composition of the Company’s net revenues recognized during the three and six months ended June 30, 2019 and 2020, disaggregated by source and nature, are as follows: For the three months ended June 30, For the six months ended June 30, 2019 2020 2019 2020 Net revenues from contracted payers* $ 489,901 $ 261,620 $ 971,320 $ 761,808 Net revenues from non-contracted payers 628,477 579,398 1,125,847 1,396,811 Development services revenues 45,081 38,453 87,579 98,782 Kits and Blood Collection Tubes (BCT) 27,864 38,000 30,816 106,619 Total net revenues $ 1,191,323 $ 917,471 $ 2,215,562 $ 2,364,020 *Includes Medicare and Medicare Advantage, as reimbursement amounts are fixed. For the three months ended June 30, For the six months ended June 30, 2019 2020 2019 2020 Net commercial revenues recognized upon delivery $ 1,118,378 $ 841,018 $ 2,009,364 $ 2,158,619 Development services revenues recognized upon delivery 45,081 38,453 87,579 98,782 Commercial revenues recognized upon cash collection — — 87,803 — Kits and Blood Collection Tubes (BCT) 27,864 38,000 30,816 106,619 Total net revenues $ 1,191,323 $ 917,471 $ 2,215,562 $ 2,364,020 Concentrations of credit risk with respect to revenues are primarily limited to geographies to which the Company provides a significant volume of its services, and to specific third-party payers of the Company’s services such as Medicare, insurance companies, and other third-party payers. The Company’s client base consists of many geographically dispersed clients diversified across various customer types. The Company's third-party payers that represent more than 10% of total net revenues in any period presented, as well as their related net revenue amount as a percentage of total net revenues, during the three and six months ended June 30, 2019 and 2020 were as follows: For the three months ended June 30, For the six months ended June 30, 2019 2020 2019 2020 Medicare and Medicare Advantage 43 % 30 % 45 % 34 % Blue Cross Blue Shield 20 % 29 % 17 % 29 % United Healthcare 8 % 8 % 10 % 6 % The Company's third-party payers that represent more than 10% of total net accounts receivable, and their related net accounts receivable balance as a percentage of total net accounts receivable, at December 31, 2019 and June 30, 2020 were as follows: December 31, 2019 June 30, 2020 Blue Cross Blue Shield 26 % 30 % Medicare and Medicare Advantage 17 % 13 % United Healthcare 12 % 11 % Aetna 7 % 11 %
Recent Accounting Pronouncements	Recent Accounting Pronouncements In November 2018, the FASB issued authoritative guidance clarifying the interaction between Collaborative Arrangements (Topic 808) and Revenue from Contracts with Customers (Topic 606) to address diversity in practice related to how companies account for collaborative arrangements. For public companies, this guidance is effective for fiscal years beginning after December 15, 2019, including interim periods within that fiscal year. Early adoption is permitted, but no earlier than an entity’s adoption date of Revenue from Contracts with Customers (Topic 606). The Company adopted this guidance for the fiscal year beginning on January 1, 2020, and determined that the adoption of this guidance does not have a material impact on its financial statements or disclosures.

The Company, Business Activit_3

The Company, Business Activities and Basis of Presentation (Tables)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Composition of Net Revenues Recognized Disaggregated by Source and Nature	The composition of the Company’s net revenues recognized during the three and six months ended June 30, 2019 and 2020, disaggregated by source and nature, are as follows: For the three months ended June 30, For the six months ended June 30, 2019 2020 2019 2020 Net revenues from contracted payers* $ 489,901 $ 261,620 $ 971,320 $ 761,808 Net revenues from non-contracted payers 628,477 579,398 1,125,847 1,396,811 Development services revenues 45,081 38,453 87,579 98,782 Kits and Blood Collection Tubes (BCT) 27,864 38,000 30,816 106,619 Total net revenues $ 1,191,323 $ 917,471 $ 2,215,562 $ 2,364,020 *Includes Medicare and Medicare Advantage, as reimbursement amounts are fixed. For the three months ended June 30, For the six months ended June 30, 2019 2020 2019 2020 Net commercial revenues recognized upon delivery $ 1,118,378 $ 841,018 $ 2,009,364 $ 2,158,619 Development services revenues recognized upon delivery 45,081 38,453 87,579 98,782 Commercial revenues recognized upon cash collection — — 87,803 — Kits and Blood Collection Tubes (BCT) 27,864 38,000 30,816 106,619 Total net revenues $ 1,191,323 $ 917,471 $ 2,215,562 $ 2,364,020
Summary of Third-Party Payers That Represent More Than 10% of Total Net Revenues and Total Net Accounts Receivable and Their Related Percentage	The Company's third-party payers that represent more than 10% of total net revenues in any period presented, as well as their related net revenue amount as a percentage of total net revenues, during the three and six months ended June 30, 2019 and 2020 were as follows: For the three months ended June 30, For the six months ended June 30, 2019 2020 2019 2020 Medicare and Medicare Advantage 43 % 30 % 45 % 34 % Blue Cross Blue Shield 20 % 29 % 17 % 29 % United Healthcare 8 % 8 % 10 % 6 % The Company's third-party payers that represent more than 10% of total net accounts receivable, and their related net accounts receivable balance as a percentage of total net accounts receivable, at December 31, 2019 and June 30, 2020 were as follows: December 31, 2019 June 30, 2020 Blue Cross Blue Shield 26 % 30 % Medicare and Medicare Advantage 17 % 13 % United Healthcare 12 % 11 % Aetna 7 % 11 %

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	6 Months Ended
	Jun. 30, 2020
Fair Value Disclosures [Abstract]
Assumptions Used for Determining Fair Values of Common Stock Warrants	The fair value of the warrants was estimated using a Black-Scholes model with the following assumptions: Beginning stock price $ 1.05 Exercise price $ 1.20 Expected dividend yield 0.00 % Discount rate-bond equivalent yield 2.49 % Expected life (in years) 5.00 Expected volatility 147.7 % Beginning stock price $ 1.12 Exercise price $ 1.25 Expected dividend yield 0.00 % Discount rate-bond equivalent yield 2.44 % Expected life (in years) 5.50 Expected volatility 140.0 % Beginning stock price $ 1.29 Exercise price $ 1.31 Expected dividend yield 0.00 % Discount rate-bond equivalent yield 2.05 % Expected life (in years) 5.50 Expected volatility 145.9 % Beginning stock price $ 0.30 Exercise price $ 0.3495 Expected dividend yield 0.00 % Discount rate-bond equivalent yield 1.66 % Expected life (in years) 5.50 Expected volatility 150.33 %

Balance Sheet Details (Tables)

Balance Sheet Details (Tables)	6 Months Ended
	Jun. 30, 2020
Balance Sheet Components [Abstract]
Schedule of Fixed Assets and Accrued Liabilities	The following provides certain balance sheet details: December 31, June 30, 2019 2020 Fixed Assets Machinery and equipment $ 2,857,538 $ 2,925,530 Furniture and office equipment 156,987 156,987 Computer equipment and software 1,552,891 1,552,891 Leasehold improvements 570,173 570,173 Construction in process 625,038 570,208 Total fixed assets, gross 5,762,627 5,775,789 Less accumulated depreciation and amortization (4,258,297 ) (4,439,063 ) Total fixed assets, net $ 1,504,330 $ 1,336,726 Accrued Liabilities Accrued payroll $ 298,855 $ 312,306 Accrued vacation 622,792 799,203 Accrued bonuses 748,742 525,034 Accrued sales commissions 89,562 88,546 Accrued other 220,253 146,709 Total accrued liabilities $ 1,980,204 $ 1,871,798

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Schedule of Right-Of-Use Lease Assets	The following schedule sets forth the components of right-of-use lease assets as of December 31, 2019 and June 30, 2020 as follows: December 31, June 30, 2019 2020 Lease right-of-use assets: Operating 729,330 $ 587,839 Finance 1,606,387 2,035,610 Total $ 2,335,717 $ 2,623,449
Schedule of Current Portion of Operating and Finance Lease Liabilities	The following schedule sets forth the current portion of operating and finance lease liabilities as of December 31, 2019 and June 30, 2020: December 31, June 30, 2019 2020 Current portion of lease liability: Operating 842,452 $ 603,999 Finance 724,329 787,361 Total $ 1,566,781 $ 1,391,360
Schedule of Long-Term Portion of Operating and Finance Lease Liabilities	The following schedule sets forth the long-term portion of operating and finance lease liabilities as of December 31, 2019 and June 30, 2020: December 31, June 30, 2019 2020 Long-term portion of lease liability: Operating $ — $ — Finance 973,189 1,301,910 Total $ 973,189 $ 1,301,910
Schedule of Lease Expenses	The following schedule represents the components of lease expense for the three and six months ended June 30, 2019 and 2020: For the three months ended June 30, For the six months ended June 30, 2019 2020 2019 2020 Lease cost Finance lease cost Amortization of right-of-use assets $ 119,599 $ 129,576 $ 229,929 $ 274,106 Interest on lease liabilities 63,574 50,975 125,548 107,672 Operating lease cost 318,005 318,005 636,010 636,010 Total $ 501,178 $ 498,556 $ 991,487 $ 1,017,788
Schedule of Remaining Future Minimum Lease Payments for Finance and Operating Leases	The following schedule sets forth the remaining future minimum lease payments outstanding under finance and operating leases, as well as corresponding remaining sales tax and maintenance obligation payments that are expensed as incurred and due within each respective year ending December 31, as well as the present value of the total amount of the remaining minimum lease payments as of June 30, 2020: Finance Operating Minimum Maintenance and Minimum Lease Sales Tax Obligation Lease Payments Payments Payments 2020 $ 471,266 $ 49,161 $ 610,810 2021 730,247 81,035 — 2022 606,797 69,481 — 2023 466,170 70,231 — Thereafter 255,733 23,163 — Total payments 2,530,213 293,071 610,810 Less amount representing interest (440,942 ) — (6,811 ) Present value of payments $ 2,089,271 $ 293,071 $ 603,999
Supplemental Cash Flow Information Related to Operating and Finance Leases	The following schedule sets forth supplemental cash flow information related to operating and finance leases as of June 30, 2020: For the six months ended June 30, 2019 2020 Other information Operating cash flows from finance leases $ 125,548 $ 107,672 Operating cash flows from operating leases $ 711,624 $ 732,973 Financing cash flows from finance leases $ 277,250 $ 311,576

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Stock Option Activity	A summary of stock option activity for the six months ended June 30, 2020 is as follows: Weighted Average Weighted Remaining Number of Average Exercise Contractual Shares Price Per Share Term in Years Outstanding at December 31, 2019 2,732,023 $ 3.66 9.25 Granted 86,739 $ 0.43 Exercised — — Cancelled/forfeited/expired (247,050 ) $ 1.78 Outstanding at June 30, 2020 2,571,712 $ 3.73 8.80 Vested and unvested expected to vest at June 30, 2020 2,514,856 $ 3.80 8.62
Assumptions Used for Determining Fair Value of Stock Options Under Black-Scholes Pricing Model	The assumptions used in the Black-Scholes pricing model for stock options granted during the six months ended June 30, 2020 were as follows: Stock and exercise prices $0.27 - $0.71 Expected dividend yield 0.00% Discount rate-bond equivalent yield 0.38% – 1.37% Expected life (in years) 5.0 – 5.96 Expected volatility 146.1% - 171.1%
Summary of RSU Activity	A summary of RSU activity for the six months ended June 30, 2020 is as follows: Weighted Number of Average Grant Shares Date Fair Value Outstanding at December 31, 2019 360 $ 415.80 Granted — — Vested and issued — — Forfeited — — Outstanding at June 30, 2020 360 $ 415.80 Vested and unvested expected to vest at June 30, 2020 360 $ 415.80
Effects of Stock-Based Compensation Related to Equity Awards to Employees and Nonemployees on Condensed Statement of Operations and Comprehensive Loss	The following table presents the effects of stock-based compensation related to equity awards to employees and nonemployees on the unaudited condensed statements of operations and comprehensive loss during the periods presented: For the three months ended For the six months ended June 30, June 30, 2019 2020 2019 2020 Stock Options Cost of revenues $ 17,073 $ 30,752 $ 25,220 $ 53,565 Research and development expenses 36,922 29,082 65,116 53,517 General and administrative expenses 145,037 103,345 192,618 197,759 Sales and marketing expenses 25,609 31,057 44,146 32,359 Total expenses related to stock options $ 224,641 $ 194,236 $ 327,100 $ 337,200

Common Stock Warrants Outstan_2

Common Stock Warrants Outstanding (Tables)	6 Months Ended
	Jun. 30, 2020
Equity Classified Warrants [Abstract]
Summary of Equity-Classified Common Stock Warrant Activity	A summary of equity-classified common stock warrant activity for the six months ended June 30, 2020 is as follows: Average Weighted Remaining Number of Average Exercise Contractual Shares Price Per Share Term in Years Outstanding at December 31, 2019 27,484,249 $ 1.86 4.6 Issued 8,854,758 0.36 Exercised (21,254,752 ) 0.67 Expired (19,339 ) 140.40 Outstanding at June 30, 2020 15,064,916 $ 2.47 4.2

Net Loss per Common Share (Tabl

Net Loss per Common Share (Tables)	6 Months Ended
	Jun. 30, 2020
Earnings Per Share [Abstract]
Schedule of Anti-Dilutive Securities Excluded from Computations of Diluted Weighted-Average Shares	The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding for the periods presented, as they would be anti-dilutive: For the six months ended June 30, 2019 2020 Preferred warrants outstanding (number of common stock equivalents) 17 — Common warrants outstanding 15,197,249 15,064,916 RSUs outstanding 360 360 Convertible preferred stock outstanding (number of common stock equivalents) 471,393 471,393 Common options outstanding 2,768,443 2,571,712 Total anti-dilutive common share equivalents 18,437,462 18,108,381

The Company, Business Activit_4

The Company, Business Activities and Basis of Presentation - Additional Information (Detail) - ASC 606 [Member]	6 Months Ended
	Jun. 30, 2020
The Company Business Activities And Basis Of Presentation [Line Items]
Performance obligation, description of timing	The duration of time between accession receipt and delivery of a valid assay result to the ordering physician or entity is typically less than two weeks.
Practical expedient, description	The Company does not adjust the transaction price for the effects of a significant financing component, as at contract inception, the Company expects the collection cycle to be one year or less.
Maximum [Member] | Sales and Marketing Expenses [Member]
The Company Business Activities And Basis Of Presentation [Line Items]
Amortization period	1 year

The Company, Business Activit_5

The Company, Business Activities and Basis of Presentation - Composition of Net Revenues Recognized Disaggregated by Source (Detail) - USD ($)		3 Months Ended		6 Months Ended
		Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Disaggregation Of Revenue [Line Items]
Total net revenues		$ 917,471	$ 1,191,323	$ 2,364,020	$ 2,215,562
Commercial Revenues [Member] | Contracted Payers [Member]
Disaggregation Of Revenue [Line Items]
Total net revenues	[1]	261,620	489,901	761,808	971,320
Commercial Revenues [Member] | Non-Contracted Payers [Member]
Disaggregation Of Revenue [Line Items]
Total net revenues		579,398	628,477	1,396,811	1,125,847
Development Services Revenues [Member]
Disaggregation Of Revenue [Line Items]
Total net revenues		38,453	45,081	98,782	87,579
Kits and Blood Collection Tubes [Member]
Disaggregation Of Revenue [Line Items]
Total net revenues		$ 38,000	$ 27,864	$ 106,619	$ 30,816
[1]	Includes Medicare and Medicare Advantage, as reimbursement amounts are fixed.

The Company, Business Activit_6

The Company, Business Activities and Basis of Presentation - Composition of Net Revenues Recognized Disaggregated by Nature (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
The Company Business Activities And Basis Of Presentation [Line Items]
Total net revenues	$ 917,471	$ 1,191,323	$ 2,364,020	$ 2,215,562
Commercial Revenues [Member] | Net Commercial Revenues Recognized Upon Delivery [Member]
The Company Business Activities And Basis Of Presentation [Line Items]
Total net revenues	841,018	1,118,378	2,158,619	2,009,364
Commercial Revenues [Member] | Commercial Revenues Recognized Upon Cash Collection [Member]
The Company Business Activities And Basis Of Presentation [Line Items]
Total net revenues				87,803
Development Services Revenues [Member]
The Company Business Activities And Basis Of Presentation [Line Items]
Total net revenues	38,453	45,081	98,782	87,579
Kits and Blood Collection Tubes [Member]
The Company Business Activities And Basis Of Presentation [Line Items]
Total net revenues	$ 38,000	$ 27,864	$ 106,619	$ 30,816

The Company, Business Activit_7

The Company, Business Activities and Basis of Presentation - Summary of Third-Party Payers That Represent More Than 10% of Total Net Revenues and Total Net Accounts Receivable and Their Related Percentage (Detail)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Customer Concentration Risk [Member] | Net Revenues [Member] | Medicare and Medicare Advantage [Member]
Concentration Risk [Line Items]
Concentration risk percentage	30.00%	43.00%	34.00%	45.00%
Customer Concentration Risk [Member] | Net Revenues [Member] | Blue Cross Blue Shield [Member]
Concentration Risk [Line Items]
Concentration risk percentage	29.00%	20.00%	29.00%	17.00%
Customer Concentration Risk [Member] | Net Revenues [Member] | United Healthcare [Member]
Concentration Risk [Line Items]
Concentration risk percentage	8.00%	8.00%	6.00%	10.00%
Credit Concentration Risk [Member] | Net Accounts Receivable [Member] | Medicare and Medicare Advantage [Member]
Concentration Risk [Line Items]
Concentration risk percentage			13.00%		17.00%
Credit Concentration Risk [Member] | Net Accounts Receivable [Member] | Blue Cross Blue Shield [Member]
Concentration Risk [Line Items]
Concentration risk percentage			30.00%		26.00%
Credit Concentration Risk [Member] | Net Accounts Receivable [Member] | United Healthcare [Member]
Concentration Risk [Line Items]
Concentration risk percentage			11.00%		12.00%
Credit Concentration Risk [Member] | Net Accounts Receivable [Member] | Aetna [Member]
Concentration Risk [Line Items]
Concentration risk percentage			11.00%		7.00%

Liquidity and Going Concern U_2

Liquidity and Going Concern Uncertainty - Additional Information (Detail) - USD ($)	Apr. 16, 2020	Mar. 04, 2020	Mar. 02, 2020	Mar. 19, 2019	Feb. 12, 2019	Jan. 18, 2019	Jan. 31, 2020	May 31, 2019	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Jan. 31, 2018
Liquidity And Managements Plans [Line Items]
Cash									$ 24,053,269				$ 24,053,269		$ 9,301,406
Accumulated deficit									(260,550,604)				(260,550,604)		(245,717,189)
Net loss									(6,489,303)	$ (8,341,338)	$ (7,816,012)	$ (5,916,787)	(14,830,641)	$ (13,732,799)	$ (25,100,000)
Aggregate net interest-bearing indebtedness									2,100,000				2,100,000
Aggregate net interest-bearing indebtedness due within one year									787,000				787,000
Other non-interest bearing current liabilities									$ 2,400,000				2,400,000
Proceeds from exercise of common stock warrants														2,337,298
Stock price	$ 0.46	$ 0.41	$ 0.40	$ 1.37		$ 2.25
Shares issued in offering	22,300,000	16,000,000	23,000,000	5,950,000		990,000
Proceeds from exercise of common stock warrants													$ 2,379,316	$ 2,513,172
Proceeds from issuance of common stock, net of issuance costs	$ 9,600,000	$ 6,100,000	$ 8,600,000	$ 7,500,000		$ 2,000,000
Warrant [Member]
Liquidity And Managements Plans [Line Items]
Issuance of warrants to purchase shares of common stock																896,578
Stock price							$ 0.3495		$ 0.3495				$ 0.3495			$ 0.405
Proceeds from exercise of common stock warrants								$ 2,500,000
Warrant [Member] | Over-allotment Option [Member]
Liquidity And Managements Plans [Line Items]
Shares issued in offering					915,000		1,927,500
Proceeds from exercise of common stock warrants							$ 700,000
February 2019 March 2019 Warrant Repricing and Exchange Transaction [Member]
Liquidity And Managements Plans [Line Items]
Proceeds from exercise of common stock warrants							$ 2,300,000						$ 2,300,000
February 2019 March 2019 Warrant Repricing and Exchange Transaction [Member] | Warrant [Member]
Liquidity And Managements Plans [Line Items]
Issuance of warrants to purchase shares of common stock							6,927,258									6,927,258
Minimum [Member]
Liquidity And Managements Plans [Line Items]
CARES ACT of 2020 percentage of decrease in commercial volume													15.00%
Maximum [Member]
Liquidity And Managements Plans [Line Items]
CARES ACT of 2020 percentage of decrease in commercial volume													25.00%
Maximum [Member] | Over-allotment Option [Member]
Liquidity And Managements Plans [Line Items]
Issuance of warrants to purchase shares of common stock					937,500

Sales of Equity Securities - Ad

Sales of Equity Securities - Additional Information (Detail) - USD ($)	Apr. 16, 2020	Mar. 04, 2020	Mar. 02, 2020	May 28, 2019	Mar. 19, 2019	Mar. 11, 2019	Feb. 12, 2019	Jan. 18, 2019	Jan. 31, 2020	May 31, 2019	Mar. 31, 2019	Feb. 28, 2019	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Jan. 10, 2020	Jan. 31, 2018
Class Of Stock [Line Items]
Shares issued in offering	22,300,000	16,000,000	23,000,000		5,950,000			990,000
Stock price	$ 0.46	$ 0.41	$ 0.40		$ 1.37			$ 2.25
Net cash proceeds from sale of securities	$ 9,600,000	$ 6,100,000	$ 8,600,000		$ 7,500,000			$ 2,000,000
Exercise price of warrants					$ 1.25		$ 1.20					$ 1.20				$ 0.3495	$ 1.20
Class of warrant or rights, term					5 years 6 months
Proceeds from exercise of common stock warrants														$ 2,379,316	$ 2,513,172
Warrant exercisable for share of common stock					1
Fair value of warrants issued									$ 1,900,000
Warrant inducement expense											$ 130,000	$ 60,000	$ 1,831,116	2,102,109	1,831,116
Proceeds from exercise of common stock warrants															$ 2,337,298
Investor Warrants [Member]
Class Of Stock [Line Items]
Exercise price of warrants				$ 1.31
Proceeds from exercise of common stock warrants				$ 2,300,000
Number of warrant exercised				2,062,966
Cash exercise of warrants description				In order to induce the Exercising Holders to cash exercise the Investor Warrants, the Exercise Agreements provided for the issuance of new warrants, or Inducement Warrants, with such Inducement Warrants to be issued in an amount equal to 75% of the number of Exercised Shares underlying any Investor Warrants that was cash exercised by July 15, 2019. The Inducement Warrants were exercisable upon issuance and terminate on the date that is five-years and six-months following the initial exercise date.
Fair value of warrants issued				$ 1,800,000
February 2019 March 2019 Warrant Repricing and Exchange Transaction [Member]
Class Of Stock [Line Items]
Warrant inducement expense									191,000
Proceeds from exercise of common stock warrants									$ 2,300,000					$ 2,300,000
Warrant [Member]
Class Of Stock [Line Items]
Stock price									$ 0.3495					$ 0.3495			$ 0.405
Issuance of warrants to purchase shares of common stock																	896,578
Proceeds from exercise of common stock warrants										$ 2,500,000
Number of warrant exercised										2,086,479
Warrant [Member] | February 2019 March 2019 Warrant Repricing and Exchange Transaction [Member]
Class Of Stock [Line Items]
Issuance of warrants to purchase shares of common stock									6,927,258								6,927,258
Follow-on Public Offering [Member]
Class Of Stock [Line Items]
Shares issued in offering							6,250,000
Stock price						$ 1.20	$ 1.20
Net cash proceeds from sale of securities						$ 592,000	$ 6,600,000
Private offering, number of common stock and warrants issued							6,250,000
Exercise price of warrants					$ 1.25		$ 1.20
Class of warrant or rights, term					5 years 6 months		5 years
Proceeds from exercise of common stock warrants							$ 0
Purchase of common stock by underwriters to cover overallotments, number of shares						538,867
Over-allotment Option [Member] | Warrant [Member]
Class Of Stock [Line Items]
Shares issued in offering							915,000		1,927,500
Proceeds from exercise of common stock warrants									$ 700,000
Maximum [Member] | Investor Warrants [Member]
Class Of Stock [Line Items]
Warrants exercisable percentage				20.00%
Maximum [Member] | Follow-on Public Offering [Member]
Class Of Stock [Line Items]
Issuance of warrants to purchase shares of common stock							6,250,000
Maximum [Member] | Over-allotment Option [Member]
Class Of Stock [Line Items]
Issuance of warrants to purchase shares of common stock							937,500

Fair Value Measurement - Additi

Fair Value Measurement - Additional Information (Detail) - USD ($)	Jan. 10, 2020	May 30, 2019	Mar. 19, 2019	Feb. 12, 2019	Mar. 31, 2019	Feb. 28, 2019	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Jan. 31, 2018
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fixed asset purchases as right-of-use asset finance lease obligations								$ 703,000	$ 149,000
Estimated grant date fair value of warrants	$ 0.28		$ 1.01	$ 0.95
Issuance of unregistered warrants to purchase shares of common stock, grant date fair value	$ 1,900,000		$ 6,000,000	$ 6,800,000
Exercise price of unregistered warrants	$ 0.3495		$ 1.25	$ 1.20		$ 1.20				$ 1.20
Class of warrant or rights, term			5 years 6 months
Adjusted exercise price of warrants					$ 1.25	1.20
Estimated fair value of warrants					0.27	0.27
Estimated fair value of warrants increased					$ 0.30	$ 0.29
Warrants eligible for price modification					4,760,000	2,167,258
Warrant inducement expense					$ 130,000	$ 60,000	$ 1,831,116	2,102,109	$ 1,831,116
Follow-on Public Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Exercise price of unregistered warrants			$ 1.25	$ 1.20
Class of warrant or rights, term			5 years 6 months	5 years
Warrant Inducement Transaction [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Estimated grant date fair value of warrants		$ 1.18
Issuance of unregistered warrants to purchase shares of common stock, grant date fair value		$ 1,800,000
Exercise price of unregistered warrants	$ 0.3495	$ 1.31
Class of warrant or rights, term	5 years 6 months	5 years 6 months
Maximum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Issuance of unregistered warrants to purchase shares of common stock	6,927,258		5,950,000	7,165,000
Maximum [Member] | Warrant Inducement Transaction [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Issuance of unregistered warrants to purchase shares of common stock		1,547,226
Estimated Fair Value Measurements, Nonrecurring [Member] | Level 3 Inputs [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fixed asset purchases as right-of-use asset finance lease obligations								$ 703,000

Fair Value Measurement - Assump

Fair Value Measurement - Assumptions Used for Determining Fair Values of Common Stock Warrants (Detail)	Jun. 30, 2020$ / shares	Apr. 16, 2020$ / shares	Mar. 04, 2020$ / shares	Mar. 02, 2020$ / shares	Mar. 19, 2019$ / shares	Jan. 18, 2019$ / shares
Warrant Fair Value Black Scholes Method [Line Items]
Beginning stock price		$ 0.46	$ 0.41	$ 0.40	$ 1.37	$ 2.25
February 12, 2019 Offering [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Beginning stock price	$ 1.05
February 12, 2019 Offering [Member] | Exercise Price [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Exercise price	1.20
February 12, 2019 Offering [Member] | Expected Dividend Yield [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Exercise price	0
February 12, 2019 Offering [Member] | Discount Rate-Bond Equivalent Yield [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Exercise price	2.49
February 12, 2019 Offering [Member] | Expected Life [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Expected life (in years)	5 years
February 12, 2019 Offering [Member] | Expected Volatility [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Exercise price	147.7
March 19, 2019 Offering [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Beginning stock price	$ 1.12
March 19, 2019 Offering [Member] | Exercise Price [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Exercise price	1.25
March 19, 2019 Offering [Member] | Expected Dividend Yield [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Exercise price	0
March 19, 2019 Offering [Member] | Discount Rate-Bond Equivalent Yield [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Exercise price	2.44
March 19, 2019 Offering [Member] | Expected Life [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Expected life (in years)	5 years 6 months
March 19, 2019 Offering [Member] | Expected Volatility [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Exercise price	140
May 30, 2019 Warrant Inducement Transaction [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Beginning stock price	$ 1.29
May 30, 2019 Warrant Inducement Transaction [Member] | Exercise Price [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Exercise price	1.31
May 30, 2019 Warrant Inducement Transaction [Member] | Expected Dividend Yield [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Exercise price	0
May 30, 2019 Warrant Inducement Transaction [Member] | Discount Rate-Bond Equivalent Yield [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Exercise price	2.05
May 30, 2019 Warrant Inducement Transaction [Member] | Expected Life [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Expected life (in years)	5 years 6 months
May 30, 2019 Warrant Inducement Transaction [Member] | Expected Volatility [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Exercise price	145.9
January 10, 2020 Warrant Inducement Transaction [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Beginning stock price	$ 0.30
January 10, 2020 Warrant Inducement Transaction [Member] | Exercise Price [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Exercise price	0.3495
January 10, 2020 Warrant Inducement Transaction [Member] | Expected Dividend Yield [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Exercise price	0
January 10, 2020 Warrant Inducement Transaction [Member] | Discount Rate-Bond Equivalent Yield [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Exercise price	1.66
January 10, 2020 Warrant Inducement Transaction [Member] | Expected Life [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Expected life (in years)	5 years 6 months
January 10, 2020 Warrant Inducement Transaction [Member] | Expected Volatility [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Exercise price	150.33

Balance Sheet Details - Schedul

Balance Sheet Details - Schedule of Fixed Assets and Accrued Liabilities (Detail) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Fixed Assets
Machinery and equipment	$ 2,925,530	$ 2,857,538
Furniture and office equipment	156,987	156,987
Computer equipment and software	1,552,891	1,552,891
Leasehold improvements	570,173	570,173
Construction in process	570,208	625,038
Total fixed assets, gross	5,775,789	5,762,627
Less accumulated depreciation and amortization	(4,439,063)	(4,258,297)
Total fixed assets, net	1,336,726	1,504,330
Accrued Liabilities
Accrued payroll	312,306	298,855
Accrued vacation	799,203	622,792
Accrued bonuses	525,034	748,742
Accrued sales commissions	88,546	89,562
Accrued other	146,709	220,253
Total accrued liabilities	$ 1,871,798	$ 1,980,204

Leases - Additional Information

Leases - Additional Information (Detail)	Jun. 05, 2020	Jun. 01, 2020USD ($)ft²	Feb. 01, 2019USD ($)	Jan. 31, 2019USD ($)mo	Jun. 30, 2020USD ($)mo	Apr. 30, 2020USD ($)mo	Mar. 31, 2020USD ($)mo	Feb. 29, 2020USD ($)mo	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Dec. 31, 2019USD ($)	Jan. 01, 2019USD ($)	Dec. 31, 2018USD ($)
Leases [Line Items]
Finance lease right-of-use assets					$ 2,035,610				$ 2,035,610		$ 2,035,610		$ 1,606,387
Total proceeds from equipment financing commitment			$ 149,000		$ 334,000	$ 161,000	$ 11,000	$ 197,000
Finance lease transaction, frequency of payments				monthly	monthly	monthly	monthly	monthly
Finance lease transaction, number of installments payments | mo				36		60	48
Finance lease transaction, monthly installments of principal and interest payments				$ 5,013	$ 8,966	$ 3,337	$ 288	$ 4,532
Finance lease transaction, total amount to be repaid				$ 180,000	$ 469,000	$ 185,000	$ 14,000	$ 265,000	469,000		469,000
Finance lease transaction, commitment period				2022-02	2025-06	2025-03	2024-02	2025-01
Operating lease monthly payments											732,973	$ 711,624
Operating lease, right-of-use asset					$ 587,839				587,839		587,839		$ 729,330
Operating lease liability					$ 603,999				$ 603,999		$ 603,999
Finance lease, weighted average remaining lease term					3 years 4 months 28 days				3 years 4 months 28 days		3 years 4 months 28 days
Operating lease, weighted average remaining lease term					1 month 2 days				1 month 2 days		1 month 2 days
Finance lease, weighted average discount rate, percent					19.69%				19.69%		19.69%
Operating lease, weighted average discount rate, percent					4.50%				4.50%		4.50%
Right of use assets in exchange for finance lease liabilities											$ 703,000
ASC Topic 842 [Member]
Leases [Line Items]
Finance lease right-of-use assets														$ 1,400,000
Financed equipment					$ 3,917,000				$ 3,917,000		3,917,000				$ 3,125,000
Accumulated depreciation related to equipment under finance leases					1,885,000				1,885,000		1,885,000				$ 1,606,000
Depreciation expense related to equipment under finance leases									130,000	$ 89,000	$ 274,000	$ 231,000
Operating lease transaction, frequency of payments											monthly cash payment
Operating lease monthly payments											$ 120,000
Operating lease term											Jul. 31, 2020
Operating lease, right-of-use asset					1,900,000				1,900,000		$ 1,900,000			1,930,000
Operating lease liability														$ 2,201,000
Operating lease incremental borrowing rate														4.50%
ASC Topic 842 [Member] | Net Machinery and Equipment [Member]
Leases [Line Items]
Finance lease right-of-use assets					1,400,000				1,400,000		1,400,000			$ 1,400,000
ASC Topic 842 [Member] | San Diego, California [Member]
Leases [Line Items]
Operating lease monthly payments		$ 128,000
Operating lease, right-of-use asset					482,000				482,000		482,000
Operating lease liability					$ 482,000				$ 482,000		$ 482,000
Lessee, operating lease, option to extend	November 30, 2020				November 2020
Lessee, operating lease, existence of option to extend	true				true
Lease agreement | ft²		39,000
Lessee, operating lease, term of contract		127 months
Initial monthly lease payments		$ 111,000
Minimum [Member]
Leases [Line Items]
Finance lease transaction, number of installments payments | mo					36			48
Minimum [Member] | ASC Topic 842 [Member]
Leases [Line Items]
Financed equipment useful life					3 years				3 years		3 years
Maximum [Member]
Leases [Line Items]
Finance lease transaction, number of installments payments | mo					60			60
Maximum [Member] | ASC Topic 842 [Member]
Leases [Line Items]
Financed equipment useful life					7 years				7 years		7 years

Leases - Schedule of Right-Of-U

Leases - Schedule of Right-Of-Use Lease Assets (Detail) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Lease right-of-use assets:
Operating	$ 587,839	$ 729,330
Finance	2,035,610	1,606,387
Total	$ 2,623,449	$ 2,335,717

Leases - Schedule of Current Po

Leases - Schedule of Current Portion of Operating and Finance Lease Liabilities (Detail) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Current portion of lease liability:
Operating	$ 603,999	$ 842,452
Finance	787,361	724,329
Total	$ 1,391,360	$ 1,566,781

Leases - Schedule of Long-Term

Leases - Schedule of Long-Term Portion of Operating and Finance Lease Liabilities (Detail) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Long-term portion of lease liability:
Finance	$ 1,301,910	$ 973,189
Total	$ 1,301,910	$ 973,189

Leases - Schedule of Lease Expe

Leases - Schedule of Lease Expense (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Finance lease cost
Amortization of right-of-use assets	$ 129,576	$ 119,599	$ 274,106	$ 229,929
Interest on lease liabilities	50,975	63,574	107,672	125,548
Operating lease cost	318,005	318,005	636,010	636,010
Total	$ 498,556	$ 501,178	$ 1,017,788	$ 991,487

Leases - Schedule of Remaining

Leases - Schedule of Remaining Future Minimum Lease Payments for Finance and Operating Leases (Detail)	Jun. 30, 2020USD ($)
Financing Lease Minimum Payment Abstract
2020	$ 471,266
2021	730,247
2022	606,797
2023	466,170
Thereafter	255,733
Total payments	2,530,213
Less amount representing interest	(440,942)
Present value of payments	2,089,271
Financing Lease Maintenance and Sales Tax Obligation Payments Abstract
2020	49,161
2021	81,035
2022	69,481
2023	70,231
Thereafter	23,163
Total payments	293,071
Present value of payments	293,071
Operating Lease Minimum Payment Abstract
2020	610,810
Total payments	610,810
Less amount representing interest	(6,811)
Present value of payments	$ 603,999

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information Related to Operating and Finance Leases (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Other information
Operating cash flows from finance leases	$ 107,672	$ 125,548
Operating cash flows from operating leases	732,973	711,624
Financing cash flows from finance leases	$ 311,576	$ 277,250

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail)	Jun. 05, 2020shares	Jun. 30, 2020USD ($)shares	Jun. 30, 2019	Jun. 30, 2020USD ($)Planshares	Jun. 30, 2019	Dec. 31, 2019USD ($)shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of equity incentive plans | Plan				2
Total Shares Outstanding		2,571,712		2,571,712		2,732,023
Unrecognized share-based compensation expense, weighted-average recognition period				2 years 9 months 18 days
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Estimated forfeitures rate		0.00%	0.00%	0.00%	0.00%
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Estimated forfeitures rate		8.00%	8.00%	8.00%	8.00%
Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Intrinsic value of options outstanding | $		$ 0		$ 0		$ 0
Intrinsic value of options exercisable | $		0		0		0
Intrinsic value of options vested and unvested expected to vest | $		0		0		$ 0
RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Intrinsic value shares, RSUs outstanding | $		100		100
Intrinsic value amount, RSUs unvested and vested expected to vest | $		$ 100		$ 100
RSUs outstanding		360		360		360
Stock Options and RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized share-based compensation expense, stock options | $		$ 1,547,918		$ 1,547,918
2013 Equity Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock options and RSUs authorized		124,211		124,211
2013 Equity Incentive Plan [Member] | Non-inducement Shares [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Increase in number of shares of common stock authorized for issuance	7,300,000
Total stock options and RSUs authorized		10,364,098		10,364,098
Stock options and RSUs issued				2,571,712
Total Shares Outstanding		2,453,885		2,453,885
Common stock, shares authorized		7,919,339		7,919,339
2013 Equity Incentive Plan [Member] | Inducement shares [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock options and RSUs authorized		118,368		118,368
Stock options and RSUs issued				117,534
Total Shares Outstanding		118,368		118,368
Common stock, shares authorized		0		0

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Option Activity (Detail) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Shares Outstanding, Beginning Balance	2,732,023
Number of Shares, Granted	86,739
Number of Shares, Cancelled/forfeited/expired	(247,050)
Number of Shares Outstanding, Ending Balance	2,571,712	2,732,023
Number of Shares, Vested and unvested expected to vest, Ending Balance	2,514,856
Weighted Average Exercise Price Per Share, Outstanding, Beginning Balance	$ 3.66
Weighted Average Exercise Price Per Share, Granted	0.43
Weighted Average Exercise Price Per Share, Cancelled/forfeited/expired	1.78
Weighted Average Exercise Price Per Share, Outstanding, Ending Balance	3.73	$ 3.66
Weighted Average Exercise Price Per Share, Vested and unvested expected to vest, Ending Balance	$ 3.80
Weighted Average Remaining Contractual Term in Years, Outstanding	8 years 9 months 18 days	9 years 3 months
Weighted Average Remaining Contractual Term in Years, Vested and unvested expected to vest	8 years 7 months 13 days

Stock-Based Compensation - Assu

Stock-Based Compensation - Assumptions Used for Determining Fair Value of Stock Options Under Black-Scholes Pricing Model (Detail)	6 Months Ended
	Jun. 30, 2020$ / shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected dividend yield	0.00%
Expected volatility, Minimum	146.10%
Expected volatility, Maximum	171.10%
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock and exercise prices	$ 0.27
Discount rate-bond equivalent yield	0.38%
Expected life (in years)	5 years
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock and exercise prices	$ 0.71
Discount rate-bond equivalent yield	1.37%
Expected life (in years)	5 years 11 months 15 days

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of RSU Activity (Detail) - RSUs [Member]	6 Months Ended
	Jun. 30, 2020$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares Outstanding, Beginning Balance | shares	360
Number of Shares, Granted | shares	0
Number of share, Vested and issued | shares	0
Number of share, Forfeited | shares	0
Number of Shares Outstanding, Ending Balance | shares	360
Number of Shares, Vested and unvested expected to vest, Ending Balance | shares	360
Weighted Average Grant Date Fair Value, Outstanding, Beginning Balance | $ / shares	$ 415.80
Weighted Average Grant Date Fair Value, Granted | $ / shares	0
Weighted Average Grant Date Fair Value, Vested and issued | $ / shares	0
Weighted Average Grant Date Fair Value, Forfeited | $ / shares	0
Weighted Average Grant Date Fair Value, Outstanding, Ending Balance | $ / shares	415.80
Weighted Average Grant Date Fair Value, Vested and unvested expected to vest, Ending Balance | $ / shares	$ 415.80

Stock-Based Compensation - Effe

Stock-Based Compensation - Effects of Stock-Based Compensation Related to Equity Awards to Employees and Nonemployees on Condensed Statement of Operations and Comprehensive Loss (Detail) - Stock Options [Member] - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	$ 194,236	$ 224,641	$ 337,200	$ 327,100
Cost of revenues [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	30,752	17,073	53,565	25,220
Research and Development Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	29,082	36,922	53,517	65,116
General and Administrative Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	103,345	145,037	197,759	192,618
Sales and Marketing Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	$ 31,057	$ 25,609	$ 32,359	$ 44,146

Common Stock Warrants Outstan_3

Common Stock Warrants Outstanding - Summary of Equity-Classified Common Stock Warrant Activity (Detail) - Warrants [Member] - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Class Of Warrant Or Right [Line Items]
Number of Shares, Outstanding, Beginning Balance	27,484,249
Number of Shares, Issued	8,854,758
Number of Shares, Exercised	(21,254,752)
Number of Shares, Expired	(19,339)
Number of Shares, Outstanding, Ending Balance	15,064,916	27,484,249
Weighted Average Exercise Price Per Share, Outstanding, Beginning Balance	$ 1.86
Weighted Average Exercise Price Per Share, Issued	0.36
Weighted Average Exercise Price Per Share, Exercised	0.67
Weighted Average Exercise Price Per Share, Expired	140.40
Weighted Average Exercise Price Per Share, Outstanding, Ending Balance	$ 2.47	$ 1.86
Average Remaining Contractual Term (in years)	4 years 2 months 12 days	4 years 7 months 6 days

Common Stock Warrants Outstan_4

Common Stock Warrants Outstanding - Additional Information (Detail) - USD ($)	Mar. 19, 2019	Jun. 30, 2020
Class Of Warrant Or Right [Line Items]
Class of warrant or rights, term	5 years 6 months
Common stock warrants outstanding, intrinsic value		$ 0
January 2020 Inducement Warrants [Member]
Class Of Warrant Or Right [Line Items]
Class of warrant or rights, term		5 years 6 months

Net Loss per Common Share - Sch

Net Loss per Common Share - Schedule of Anti-Dilutive Securities Excluded from Computations of Diluted Weighted-Average Shares (Detail) - shares	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	18,108,381	18,437,462
Preferred Warrants Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents		17
Common Warrants Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	15,064,916	15,197,249
RSUs [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	360	360
Common Options Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	2,571,712	2,768,443
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	471,393	471,393

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Loss Contingencies [Line Items]
Total expense for sales tax and maintenance obligations	$ 30,000	$ 23,000	$ 62,000	$ 47,000
Total amounts for future sales tax and maintenance obligations	293,071		293,071
Accrued Other Liabilities [Member]
Loss Contingencies [Line Items]
Sales tax and maintenance obligations incurred but not paid	$ 75,000		$ 75,000		$ 78,000

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($)	Jan. 01, 2019	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Related Party Transaction [Line Items]
Revenues		$ 917,471	$ 1,191,323	$ 2,364,020	$ 2,215,562
Development Services Revenues [Member]
Related Party Transaction [Line Items]
Revenues		38,453	$ 45,081	98,782	$ 87,579
Aegea Biotechnologies, Inc [Member]
Related Party Transaction [Line Items]
Reimbursement for shared patent costs						$ 26,000	$ 19,000
Percentage of royalty on sale of product	10.00%
Accrued royalty expense		3,000		3,000		$ 7,500
Accounts receivable		2,100		$ 2,100
Aegea Biotechnologies, Inc [Member] | Development Services Revenues [Member]
Related Party Transaction [Line Items]
Revenues		$ 2,100

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - $ / shares	Aug. 07, 2020	Aug. 07, 2020	Jun. 30, 2020	Apr. 16, 2020	Mar. 04, 2020	Mar. 02, 2020	Jan. 31, 2020	Mar. 19, 2019	Jan. 18, 2019	Jan. 31, 2018
Subsequent Event [Line Items]
Stock price				$ 0.46	$ 0.41	$ 0.40		$ 1.37	$ 2.25
Warrant [Member]
Subsequent Event [Line Items]
Stock price			$ 0.3495				$ 0.3495			$ 0.405
Subsequent Event [Member]
Subsequent Event [Line Items]
Number of common stock warrants exercised	33,333
Subsequent Event [Member] | Warrant [Member]
Subsequent Event [Line Items]
Stock price	$ 0.3495	$ 0.3495
Subsequent Event [Member] | Cashless Warrants [Member]
Subsequent Event [Line Items]
Number of common stock warrants exercised		5,027,667
Common stock shares issued upon warrants exercised		2,687,744